{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "1ae0c9cc",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import matplotlib.pyplot as plt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "19d13192",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Sample ID</th>\n",
       "      <th>Patient Name</th>\n",
       "      <th>Gender</th>\n",
       "      <th>DOB</th>\n",
       "      <th>Test Name</th>\n",
       "      <th>Unit</th>\n",
       "      <th>Category</th>\n",
       "      <th>Result</th>\n",
       "      <th>DOS</th>\n",
       "      <th>Standard Test Name</th>\n",
       "      <th>Lab</th>\n",
       "      <th>Age</th>\n",
       "      <th>Outcome</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>118</td>\n",
       "      <td>Xalil Ahmad Mhamad</td>\n",
       "      <td>Male</td>\n",
       "      <td>16/04/1959</td>\n",
       "      <td>Blood Sugar</td>\n",
       "      <td>mg/dl</td>\n",
       "      <td>Diabetes Test</td>\n",
       "      <td>95</td>\n",
       "      <td>16/04/2023</td>\n",
       "      <td>Blood Sugar</td>\n",
       "      <td>Biolab</td>\n",
       "      <td>64.0</td>\n",
       "      <td>normal</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>126</td>\n",
       "      <td>Dyar Omar</td>\n",
       "      <td>Male</td>\n",
       "      <td>16/04/1986</td>\n",
       "      <td>Blood Sugar</td>\n",
       "      <td>mg/dl</td>\n",
       "      <td>Diabetes Test</td>\n",
       "      <td>86</td>\n",
       "      <td>16/04/2023</td>\n",
       "      <td>Blood Sugar</td>\n",
       "      <td>Biolab</td>\n",
       "      <td>37.0</td>\n",
       "      <td>normal</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>132</td>\n",
       "      <td>Fatah Mhamad Qadr</td>\n",
       "      <td>Male</td>\n",
       "      <td>16/04/1970</td>\n",
       "      <td>Blood Sugar</td>\n",
       "      <td>mg/dl</td>\n",
       "      <td>Diabetes Test</td>\n",
       "      <td>84</td>\n",
       "      <td>16/04/2023</td>\n",
       "      <td>Blood Sugar</td>\n",
       "      <td>Biolab</td>\n",
       "      <td>53.0</td>\n",
       "      <td>normal</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>177</td>\n",
       "      <td>Sesna Qubad Anwar</td>\n",
       "      <td>Female</td>\n",
       "      <td>17/04/1973</td>\n",
       "      <td>Blood Sugar</td>\n",
       "      <td>mg/dl</td>\n",
       "      <td>Diabetes Test</td>\n",
       "      <td>84</td>\n",
       "      <td>17/04/2023</td>\n",
       "      <td>Blood Sugar</td>\n",
       "      <td>Biolab</td>\n",
       "      <td>50.0</td>\n",
       "      <td>normal</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>179</td>\n",
       "      <td>Bayan Abdulla Abdurahman</td>\n",
       "      <td>Female</td>\n",
       "      <td>17/04/1981</td>\n",
       "      <td>Blood Sugar</td>\n",
       "      <td>mg/dl</td>\n",
       "      <td>Diabetes Test</td>\n",
       "      <td>96</td>\n",
       "      <td>17/04/2023</td>\n",
       "      <td>Blood Sugar</td>\n",
       "      <td>Biolab</td>\n",
       "      <td>42.0</td>\n",
       "      <td>normal</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Sample ID              Patient Name  Gender         DOB    Test Name  \\\n",
       "0        118        Xalil Ahmad Mhamad    Male  16/04/1959  Blood Sugar   \n",
       "1        126                 Dyar Omar    Male  16/04/1986  Blood Sugar   \n",
       "2        132         Fatah Mhamad Qadr    Male  16/04/1970  Blood Sugar   \n",
       "3        177         Sesna Qubad Anwar  Female  17/04/1973  Blood Sugar   \n",
       "4        179  Bayan Abdulla Abdurahman  Female  17/04/1981  Blood Sugar   \n",
       "\n",
       "    Unit       Category Result         DOS Standard Test Name     Lab   Age  \\\n",
       "0  mg/dl  Diabetes Test     95  16/04/2023        Blood Sugar  Biolab  64.0   \n",
       "1  mg/dl  Diabetes Test     86  16/04/2023        Blood Sugar  Biolab  37.0   \n",
       "2  mg/dl  Diabetes Test     84  16/04/2023        Blood Sugar  Biolab  53.0   \n",
       "3  mg/dl  Diabetes Test     84  17/04/2023        Blood Sugar  Biolab  50.0   \n",
       "4  mg/dl  Diabetes Test     96  17/04/2023        Blood Sugar  Biolab  42.0   \n",
       "\n",
       "  Outcome  \n",
       "0  normal  \n",
       "1  normal  \n",
       "2  normal  \n",
       "3  normal  \n",
       "4  normal  "
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.read_csv('../df_cleaned.csv', encoding='latin-1')\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "26938aa7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=== MAIN DATASET STRUCTURE ===\n",
      "Shape: (139737, 13)\n",
      "Columns: ['Sample ID', 'Patient Name', 'Gender', 'DOB', 'Test Name', 'Unit', 'Category', 'Result', 'DOS', 'Standard Test Name', 'Lab', 'Age', 'Outcome']\n",
      "Sample data:\n",
      "   Sample ID              Patient Name  Gender         DOB    Test Name  \\\n",
      "0        118        Xalil Ahmad Mhamad    Male  16/04/1959  Blood Sugar   \n",
      "1        126                 Dyar Omar    Male  16/04/1986  Blood Sugar   \n",
      "2        132         Fatah Mhamad Qadr    Male  16/04/1970  Blood Sugar   \n",
      "3        177         Sesna Qubad Anwar  Female  17/04/1973  Blood Sugar   \n",
      "4        179  Bayan Abdulla Abdurahman  Female  17/04/1981  Blood Sugar   \n",
      "\n",
      "    Unit       Category Result         DOS Standard Test Name     Lab   Age  \\\n",
      "0  mg/dl  Diabetes Test     95  16/04/2023        Blood Sugar  Biolab  64.0   \n",
      "1  mg/dl  Diabetes Test     86  16/04/2023        Blood Sugar  Biolab  37.0   \n",
      "2  mg/dl  Diabetes Test     84  16/04/2023        Blood Sugar  Biolab  53.0   \n",
      "3  mg/dl  Diabetes Test     84  17/04/2023        Blood Sugar  Biolab  50.0   \n",
      "4  mg/dl  Diabetes Test     96  17/04/2023        Blood Sugar  Biolab  42.0   \n",
      "\n",
      "  Outcome  \n",
      "0  normal  \n",
      "1  normal  \n",
      "2  normal  \n",
      "3  normal  \n",
      "4  normal  \n",
      "\n",
      "=== AGE DISTRIBUTION ===\n",
      "count    139737.000000\n",
      "mean         39.326127\n",
      "std          19.854340\n",
      "min           0.000000\n",
      "25%          26.000000\n",
      "50%          39.000000\n",
      "75%          52.000000\n",
      "max         106.000000\n",
      "Name: Age, dtype: float64\n",
      "\n",
      "=== LAB DISTRIBUTION ===\n",
      "Lab\n",
      "Biolab     74433\n",
      "Hawkari    63003\n",
      "Darugha     2301\n",
      "Name: count, dtype: int64\n",
      "Lab percentages:\n",
      "Lab\n",
      "Biolab     53.266493\n",
      "Hawkari    45.086842\n",
      "Darugha     1.646665\n",
      "Name: proportion, dtype: float64\n",
      "\n",
      "=== GENDER DISTRIBUTION ===\n",
      "Gender\n",
      "Female    88918\n",
      "Male      50819\n",
      "Name: count, dtype: int64\n",
      "Gender percentages:\n",
      "Gender\n",
      "Female    63.632395\n",
      "Male      36.367605\n",
      "Name: proportion, dtype: float64\n",
      "\n",
      "=== OUTCOME DISTRIBUTION ===\n",
      "Outcome\n",
      "normal      103085\n",
      "abnormal     36652\n",
      "Name: count, dtype: int64\n",
      "Outcome percentages:\n",
      "Outcome\n",
      "normal      73.770726\n",
      "abnormal    26.229274\n",
      "Name: proportion, dtype: float64\n",
      "\n",
      "=== DATA QUALITY CHECK ===\n",
      "Patient Name: 0 null values (0.00%)\n",
      "Standard Test Name: 0 null values (0.00%)\n",
      "Outcome: 0 null values (0.00%)\n",
      "Result: 0 null values (0.00%)\n",
      "Gender: 0 null values (0.00%)\n",
      "Lab: 0 null values (0.00%)\n",
      "\n",
      "=== AVAILABLE TESTS ===\n",
      "Total unique tests: 42\n",
      "Top 10 most common tests:\n",
      "Standard Test Name\n",
      "TSH                            12452\n",
      "Serum Creatinine                9268\n",
      "Blood Glucose                   8977\n",
      "Vitamin D3                      6841\n",
      "Complete Blood Count            6163\n",
      "C-Reactive Protein Titer        6019\n",
      "HbA1c                           5088\n",
      "Hepatitis B Surface Antigen     5025\n",
      "Total Serum Bilirubin           5020\n",
      "Hepatitis C Antibody            5007\n",
      "Name: count, dtype: int64\n"
     ]
    }
   ],
   "source": [
    "# Prepare the dataframe for classification and create dataframes for each test combination\n",
    "\n",
    "# First, let's examine the structure of our main dataset\n",
    "print(\"=== MAIN DATASET STRUCTURE ===\")\n",
    "print(f\"Shape: {df.shape}\")\n",
    "print(f\"Columns: {df.columns.tolist()}\")\n",
    "print(f\"Sample data:\")\n",
    "print(df.head())\n",
    "\n",
    "# Check the age distribution\n",
    "print(f\"\\n=== AGE DISTRIBUTION ===\")\n",
    "print(df['Age'].describe())\n",
    "\n",
    "# Check the Lab distribution\n",
    "print(f\"\\n=== LAB DISTRIBUTION ===\")\n",
    "print(df['Lab'].value_counts())\n",
    "print(f\"Lab percentages:\")\n",
    "print(df['Lab'].value_counts(normalize=True) * 100)\n",
    "\n",
    "# Check the Gender distribution\n",
    "print(f\"\\n=== GENDER DISTRIBUTION ===\")\n",
    "print(df['Gender'].value_counts())\n",
    "print(f\"Gender percentages:\")\n",
    "print(df['Gender'].value_counts(normalize=True) * 100)\n",
    "\n",
    "# Check the outcome distribution\n",
    "print(f\"\\n=== OUTCOME DISTRIBUTION ===\")\n",
    "print(df['Outcome'].value_counts())\n",
    "print(f\"Outcome percentages:\")\n",
    "print(df['Outcome'].value_counts(normalize=True) * 100)\n",
    "\n",
    "# Check for null values in key columns\n",
    "print(f\"\\n=== DATA QUALITY CHECK ===\")\n",
    "key_columns = ['Patient Name', 'Standard Test Name', 'Outcome', 'Result', 'Gender', 'Lab']\n",
    "for col in key_columns:\n",
    "    if col in df.columns:\n",
    "        null_count = df[col].isnull().sum()\n",
    "        print(f\"{col}: {null_count} null values ({null_count/len(df)*100:.2f}%)\")\n",
    "\n",
    "# Get unique test names to understand what we're working with\n",
    "print(f\"\\n=== AVAILABLE TESTS ===\")\n",
    "print(f\"Total unique tests: {df['Standard Test Name'].nunique()}\")\n",
    "test_counts = df['Standard Test Name'].value_counts()\n",
    "print(f\"Top 10 most common tests:\")\n",
    "print(test_counts.head(10))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "a3591666",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total unique tests after filtering: 42\n",
      "Pivot table shape: (31906, 42)\n",
      "Patients: 31906, Tests: 42\n",
      "Total subsets of size 3: 11480\n",
      "\n",
      "Subsets of 3 tests with more than 1000 patients:\n",
      "Found 30 qualifying subsets\n",
      "\n",
      "================================================================================\n",
      "Rank 30: ('Hepatitis B Surface Antigen', 'Hepatitis C Antibody', 'HIV Antibody') - 4843 patients\n",
      "Rank 29: ('TSH', 'Serum Creatinine', 'Blood Glucose') - 2898 patients\n",
      "Rank 28: ('Serum Creatinine', 'Total Serum Bilirubin', 'Blood Glucose') - 2880 patients\n",
      "Rank 27: ('TSH', 'Serum Creatinine', 'Total Serum Bilirubin') - 2171 patients\n",
      "Rank 26: ('TSH', 'Total Serum Bilirubin', 'Blood Glucose') - 2036 patients\n",
      "Rank 25: ('Serum Cholesterol', 'Serum Triglycerides', 'Serum LDL Cholesterol') - 1884 patients\n",
      "Rank 24: ('Serum Creatinine', 'Blood Glucose', 'C-Reactive Protein Titer') - 1703 patients\n",
      "Rank 23: ('Serum Cholesterol', 'Serum HDL Cholesterol', 'Serum LDL Cholesterol') - 1579 patients\n",
      "Rank 22: ('Serum Triglycerides', 'Serum HDL Cholesterol', 'Serum LDL Cholesterol') - 1573 patients\n",
      "Rank 21: ('Serum Cholesterol', 'Serum Triglycerides', 'Serum HDL Cholesterol') - 1572 patients\n",
      "Rank 20: ('Serum Creatinine', 'Aspartate Aminotransferase (AST)', 'Alanine Aminotransferase (ALT)') - 1354 patients\n",
      "Rank 19: ('HbA1c', 'Serum Creatinine', 'Blood Glucose') - 1208 patients\n",
      "Rank 18: ('Total Cholesterol', 'Triglycerides', 'LDL Cholesterol') - 1120 patients\n",
      "Rank 17: ('Aspartate Aminotransferase (AST)', 'Alanine Aminotransferase (ALT)', 'Alkaline Phosphatase') - 1111 patients\n",
      "Rank 16: ('Serum Creatinine', 'Serum Ferritin', 'Blood Glucose') - 1101 patients\n",
      "Rank 15: ('Serum Creatinine', 'Blood Glucose', 'LDL Cholesterol') - 1088 patients\n",
      "Rank 14: ('Serum Creatinine', 'Total Serum Bilirubin', 'C-Reactive Protein Titer') - 1072 patients\n",
      "Rank 13: ('Aspartate Aminotransferase (AST)', 'Alanine Aminotransferase (ALT)', 'Total Serum Bilirubin') - 1060 patients\n",
      "Rank 12: ('TSH', 'Total Cholesterol', 'LDL Cholesterol') - 1048 patients\n",
      "Rank 11: ('Blood Glucose', 'Total Cholesterol', 'LDL Cholesterol') - 1041 patients\n",
      "Rank 10: ('TSH', 'Serum Creatinine', 'Serum Ferritin') - 1039 patients\n",
      "Rank 9: ('Hepatitis B Surface Antigen', 'Hepatitis C Antibody', 'Blood Glucose') - 1035 patients\n",
      "Rank 8: ('Hepatitis B Surface Antigen', 'HIV Antibody', 'Blood Glucose') - 1034 patients\n",
      "Rank 7: ('Hepatitis C Antibody', 'HIV Antibody', 'Blood Glucose') - 1034 patients\n",
      "Rank 6: ('Total Serum Bilirubin', 'Blood Glucose', 'C-Reactive Protein Titer') - 1031 patients\n",
      "Rank 5: ('TSH', 'Serum Ferritin', 'Blood Glucose') - 1027 patients\n",
      "Rank 4: ('Serum Creatinine', 'Total Cholesterol', 'LDL Cholesterol') - 1024 patients\n",
      "Rank 3: ('TSH', 'Serum Creatinine', 'C-Reactive Protein Titer') - 1013 patients\n",
      "Rank 2: ('TSH', 'Serum Creatinine', 'LDL Cholesterol') - 1004 patients\n",
      "Rank 1: ('Blood Urea Nitrogen', 'Serum Creatinine', 'Blood Glucose') - 1003 patients\n",
      "\n",
      "=== TOP SUBSETS DATAFRAME ===\n",
      "                                                                                         subset  count                                                                                     tests\n",
      "                        ('Hepatitis B Surface Antigen', 'Hepatitis C Antibody', 'HIV Antibody')   4843                         [Hepatitis B Surface Antigen, Hepatitis C Antibody, HIV Antibody]\n",
      "                                                   ('TSH', 'Serum Creatinine', 'Blood Glucose')   2898                                                    [TSH, Serum Creatinine, Blood Glucose]\n",
      "                                 ('Serum Creatinine', 'Total Serum Bilirubin', 'Blood Glucose')   2880                                  [Serum Creatinine, Total Serum Bilirubin, Blood Glucose]\n",
      "                                           ('TSH', 'Serum Creatinine', 'Total Serum Bilirubin')   2171                                            [TSH, Serum Creatinine, Total Serum Bilirubin]\n",
      "                                              ('TSH', 'Total Serum Bilirubin', 'Blood Glucose')   2036                                               [TSH, Total Serum Bilirubin, Blood Glucose]\n",
      "                          ('Serum Cholesterol', 'Serum Triglycerides', 'Serum LDL Cholesterol')   1884                           [Serum Cholesterol, Serum Triglycerides, Serum LDL Cholesterol]\n",
      "                              ('Serum Creatinine', 'Blood Glucose', 'C-Reactive Protein Titer')   1703                               [Serum Creatinine, Blood Glucose, C-Reactive Protein Titer]\n",
      "                        ('Serum Cholesterol', 'Serum HDL Cholesterol', 'Serum LDL Cholesterol')   1579                         [Serum Cholesterol, Serum HDL Cholesterol, Serum LDL Cholesterol]\n",
      "                      ('Serum Triglycerides', 'Serum HDL Cholesterol', 'Serum LDL Cholesterol')   1573                       [Serum Triglycerides, Serum HDL Cholesterol, Serum LDL Cholesterol]\n",
      "                          ('Serum Cholesterol', 'Serum Triglycerides', 'Serum HDL Cholesterol')   1572                           [Serum Cholesterol, Serum Triglycerides, Serum HDL Cholesterol]\n",
      "     ('Serum Creatinine', 'Aspartate Aminotransferase (AST)', 'Alanine Aminotransferase (ALT)')   1354      [Serum Creatinine, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT)]\n",
      "                                                 ('HbA1c', 'Serum Creatinine', 'Blood Glucose')   1208                                                  [HbA1c, Serum Creatinine, Blood Glucose]\n",
      "                                      ('Total Cholesterol', 'Triglycerides', 'LDL Cholesterol')   1120                                       [Total Cholesterol, Triglycerides, LDL Cholesterol]\n",
      " ('Aspartate Aminotransferase (AST)', 'Alanine Aminotransferase (ALT)', 'Alkaline Phosphatase')   1111  [Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase]\n",
      "                                        ('Serum Creatinine', 'Serum Ferritin', 'Blood Glucose')   1101                                         [Serum Creatinine, Serum Ferritin, Blood Glucose]\n",
      "                                       ('Serum Creatinine', 'Blood Glucose', 'LDL Cholesterol')   1088                                        [Serum Creatinine, Blood Glucose, LDL Cholesterol]\n",
      "                      ('Serum Creatinine', 'Total Serum Bilirubin', 'C-Reactive Protein Titer')   1072                       [Serum Creatinine, Total Serum Bilirubin, C-Reactive Protein Titer]\n",
      "('Aspartate Aminotransferase (AST)', 'Alanine Aminotransferase (ALT)', 'Total Serum Bilirubin')   1060 [Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Total Serum Bilirubin]\n",
      "                                                ('TSH', 'Total Cholesterol', 'LDL Cholesterol')   1048                                                 [TSH, Total Cholesterol, LDL Cholesterol]\n",
      "                                      ('Blood Glucose', 'Total Cholesterol', 'LDL Cholesterol')   1041                                       [Blood Glucose, Total Cholesterol, LDL Cholesterol]\n",
      "                                                  ('TSH', 'Serum Creatinine', 'Serum Ferritin')   1039                                                   [TSH, Serum Creatinine, Serum Ferritin]\n",
      "                       ('Hepatitis B Surface Antigen', 'Hepatitis C Antibody', 'Blood Glucose')   1035                        [Hepatitis B Surface Antigen, Hepatitis C Antibody, Blood Glucose]\n",
      "                               ('Hepatitis B Surface Antigen', 'HIV Antibody', 'Blood Glucose')   1034                                [Hepatitis B Surface Antigen, HIV Antibody, Blood Glucose]\n",
      "                                      ('Hepatitis C Antibody', 'HIV Antibody', 'Blood Glucose')   1034                                       [Hepatitis C Antibody, HIV Antibody, Blood Glucose]\n",
      "                         ('Total Serum Bilirubin', 'Blood Glucose', 'C-Reactive Protein Titer')   1031                          [Total Serum Bilirubin, Blood Glucose, C-Reactive Protein Titer]\n",
      "                                                     ('TSH', 'Serum Ferritin', 'Blood Glucose')   1027                                                      [TSH, Serum Ferritin, Blood Glucose]\n",
      "                                   ('Serum Creatinine', 'Total Cholesterol', 'LDL Cholesterol')   1024                                    [Serum Creatinine, Total Cholesterol, LDL Cholesterol]\n",
      "                                        ('TSH', 'Serum Creatinine', 'C-Reactive Protein Titer')   1013                                         [TSH, Serum Creatinine, C-Reactive Protein Titer]\n",
      "                                                 ('TSH', 'Serum Creatinine', 'LDL Cholesterol')   1004                                                  [TSH, Serum Creatinine, LDL Cholesterol]\n",
      "                                   ('Blood Urea Nitrogen', 'Serum Creatinine', 'Blood Glucose')   1003                                    [Blood Urea Nitrogen, Serum Creatinine, Blood Glucose]\n"
     ]
    }
   ],
   "source": [
    "from itertools import combinations\n",
    "\n",
    "# bring back all the patients that are tested for v tests.\n",
    "# with more than 300 patients\n",
    "\n",
    "unique_tests = df['Standard Test Name'].unique()\n",
    "print(f\"Total unique tests after filtering: {len(unique_tests)}\")\n",
    "\n",
    "limit = 1000\n",
    "v = 3\n",
    "\n",
    "# Create a pivot table with patients as rows and tests as columns\n",
    "# Count how many times each patient had each test (binary: 1 if tested, 0 if not)\n",
    "df_pivot = df.groupby(['Patient Name', 'Standard Test Name']).size().unstack(fill_value=0)\n",
    "# Convert to binary (1 if patient had the test, 0 if not)\n",
    "df_pivot = (df_pivot > 0).astype(int)\n",
    "\n",
    "print(f\"Pivot table shape: {df_pivot.shape}\")\n",
    "print(f\"Patients: {len(df_pivot)}, Tests: {len(df_pivot.columns)}\")\n",
    "\n",
    "# for each subset of v items together in unique_tests,\n",
    "# we find the subset that has more than limit patients\n",
    "subsets = list(combinations(unique_tests, v))\n",
    "print(f\"Total subsets of size {v}: {len(subsets)}\")\n",
    "\n",
    "# Initialize results list\n",
    "results = []\n",
    "\n",
    "for subset in subsets:\n",
    "    # Handle subsets of any size, not just pairs\n",
    "    if len(subset) >= 2:\n",
    "        # Check if all tests in subset exist in our pivot table\n",
    "        available_tests = [test for test in subset if test in df_pivot.columns]\n",
    "        \n",
    "        if len(available_tests) == len(subset):\n",
    "            # Create a boolean mask for patients who have all tests in the subset\n",
    "            mask = df_pivot[available_tests[0]] > 0\n",
    "            for test in available_tests[1:]:\n",
    "                mask = mask & (df_pivot[test] > 0)\n",
    "            \n",
    "            count = mask.sum()\n",
    "            if count > limit:\n",
    "                # Store results in a list for creating DataFrame\n",
    "                results.append({\n",
    "                    'subset': str(subset),\n",
    "                    'count': count,\n",
    "                    'tests': list(subset)\n",
    "                })\n",
    "\n",
    "\n",
    "# Create DataFrame from results\n",
    "results_df = pd.DataFrame(results)\n",
    "\n",
    "# Sort by count in descending order\n",
    "results_df = results_df.sort_values('count', ascending=False)\n",
    "\n",
    "print(f\"\\nSubsets of {v} tests with more than {limit} patients:\")\n",
    "print(f\"Found {len(results_df)} qualifying subsets\")\n",
    "print(\"\\n\" + \"=\"*80)\n",
    "for i, row in results_df.iterrows():\n",
    "    print(f\"Rank {len(results_df) - list(results_df.index).index(i)}: {row['subset']} - {row['count']} patients\")\n",
    "\n",
    "# Display as DataFrame\n",
    "print(f\"\\n=== TOP SUBSETS DATAFRAME ===\")\n",
    "print(results_df.to_string(index=False))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "2565f6da",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=== OUTCOME DISTRIBUTION ANALYSIS FOR TEST COMBINATIONS ===\n",
      "Analyzing 30 test combinations with >1000 patients each\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Hepatitis B Surface Antigen + Hepatitis C Antibody + HIV Antibody\n",
      "ğŸ“Š Total Patients: 4,843\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Hepatitis B Surface Antigen:\n",
      "   Total Records: 5,005\n",
      "   âœ… Normal: 4,995 (99.8%)\n",
      "   âŒ Abnormal: 10 (0.2%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 3,092 (61.8%)\n",
      "      Male: 1,913 (38.2%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Biolab: 2,487 (49.7%)\n",
      "      Hawkari: 2,477 (49.5%)\n",
      "      Darugha: 41 (0.8%)\n",
      "\n",
      "ğŸ“‹ Hepatitis C Antibody:\n",
      "   Total Records: 5,000\n",
      "   âœ… Normal: 5,000 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 3,089 (61.8%)\n",
      "      Male: 1,911 (38.2%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Biolab: 2,483 (49.7%)\n",
      "      Hawkari: 2,476 (49.5%)\n",
      "      Darugha: 41 (0.8%)\n",
      "\n",
      "ğŸ“‹ HIV Antibody:\n",
      "   Total Records: 5,000\n",
      "   âœ… Normal: 4,999 (100.0%)\n",
      "   âŒ Abnormal: 1 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 3,089 (61.8%)\n",
      "      Male: 1,911 (38.2%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Biolab: 2,483 (49.7%)\n",
      "      Hawkari: 2,476 (49.5%)\n",
      "      Darugha: 41 (0.8%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (4843 patients):\n",
      "   ğŸ“Š Hepatitis: normal + Hepatitis: normal + HIV Antibody: normal\n",
      "      4,833 patients (99.8%)\n",
      "   ğŸ“Š Hepatitis: abnormal + Hepatitis: normal + HIV Antibody: normal\n",
      "      9 patients (0.2%)\n",
      "   ğŸ“Š Hepatitis: normal + Hepatitis: normal + HIV Antibody: abnormal\n",
      "      1 patients (0.0%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 4,833 (99.8%)\n",
      "   Two or More Tests Abnormal: 0 (0.0%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: TSH + Serum Creatinine + Blood Glucose\n",
      "ğŸ“Š Total Patients: 2,898\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ TSH:\n",
      "   Total Records: 3,593\n",
      "   âœ… Normal: 2,576 (71.7%)\n",
      "   âŒ Abnormal: 1,017 (28.3%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 2,584 (71.9%)\n",
      "      Male: 1,009 (28.1%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 3,171 (88.3%)\n",
      "      Biolab: 422 (11.7%)\n",
      "\n",
      "ğŸ“‹ Serum Creatinine:\n",
      "   Total Records: 3,524\n",
      "   âœ… Normal: 2,226 (63.2%)\n",
      "   âŒ Abnormal: 1,298 (36.8%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 2,413 (68.5%)\n",
      "      Male: 1,111 (31.5%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 3,131 (88.8%)\n",
      "      Biolab: 393 (11.2%)\n",
      "\n",
      "ğŸ“‹ Blood Glucose:\n",
      "   Total Records: 3,432\n",
      "   âœ… Normal: 3,432 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 2,380 (69.3%)\n",
      "      Male: 1,052 (30.7%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 3,109 (90.6%)\n",
      "      Biolab: 323 (9.4%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (2898 patients):\n",
      "   ğŸ“Š TSH: normal + Serum Creatinine: normal + Blood Glucose: normal\n",
      "      1,416 patients (48.9%)\n",
      "   ğŸ“Š TSH: normal + Serum Creatinine: abnormal + Blood Glucose: normal\n",
      "      825 patients (28.5%)\n",
      "   ğŸ“Š TSH: abnormal + Serum Creatinine: normal + Blood Glucose: normal\n",
      "      410 patients (14.1%)\n",
      "   ğŸ“Š TSH: abnormal + Serum Creatinine: abnormal + Blood Glucose: normal\n",
      "      247 patients (8.5%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 1,416 (48.9%)\n",
      "   Two or More Tests Abnormal: 247 (8.5%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Serum Creatinine + Total Serum Bilirubin + Blood Glucose\n",
      "ğŸ“Š Total Patients: 2,880\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Serum Creatinine:\n",
      "   Total Records: 3,542\n",
      "   âœ… Normal: 2,243 (63.3%)\n",
      "   âŒ Abnormal: 1,299 (36.7%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 2,421 (68.4%)\n",
      "      Male: 1,121 (31.6%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 3,382 (95.5%)\n",
      "      Biolab: 160 (4.5%)\n",
      "\n",
      "ğŸ“‹ Total Serum Bilirubin:\n",
      "   Total Records: 3,206\n",
      "   âœ… Normal: 3,206 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 2,174 (67.8%)\n",
      "      Male: 1,032 (32.2%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 3,098 (96.6%)\n",
      "      Biolab: 108 (3.4%)\n",
      "\n",
      "ğŸ“‹ Blood Glucose:\n",
      "   Total Records: 3,402\n",
      "   âœ… Normal: 3,402 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 2,348 (69.0%)\n",
      "      Male: 1,054 (31.0%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 3,334 (98.0%)\n",
      "      Biolab: 68 (2.0%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (2880 patients):\n",
      "   ğŸ“Š Serum Creatinine: normal + Total: normal + Blood Glucose: normal\n",
      "      1,844 patients (64.0%)\n",
      "   ğŸ“Š Serum Creatinine: abnormal + Total: normal + Blood Glucose: normal\n",
      "      1,036 patients (36.0%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 1,844 (64.0%)\n",
      "   Two or More Tests Abnormal: 0 (0.0%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: TSH + Serum Creatinine + Total Serum Bilirubin\n",
      "ğŸ“Š Total Patients: 2,171\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ TSH:\n",
      "   Total Records: 2,564\n",
      "   âœ… Normal: 1,866 (72.8%)\n",
      "   âŒ Abnormal: 698 (27.2%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,850 (72.2%)\n",
      "      Male: 714 (27.8%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 2,452 (95.6%)\n",
      "      Biolab: 112 (4.4%)\n",
      "\n",
      "ğŸ“‹ Serum Creatinine:\n",
      "   Total Records: 2,619\n",
      "   âœ… Normal: 1,633 (62.4%)\n",
      "   âŒ Abnormal: 986 (37.6%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,843 (70.4%)\n",
      "      Male: 776 (29.6%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 2,497 (95.3%)\n",
      "      Biolab: 122 (4.7%)\n",
      "\n",
      "ğŸ“‹ Total Serum Bilirubin:\n",
      "   Total Records: 2,370\n",
      "   âœ… Normal: 2,370 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,656 (69.9%)\n",
      "      Male: 714 (30.1%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 2,291 (96.7%)\n",
      "      Biolab: 79 (3.3%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (2171 patients):\n",
      "   ğŸ“Š TSH: normal + Serum Creatinine: normal + Total: normal\n",
      "      1,053 patients (48.5%)\n",
      "   ğŸ“Š TSH: normal + Serum Creatinine: abnormal + Total: normal\n",
      "      634 patients (29.2%)\n",
      "   ğŸ“Š TSH: abnormal + Serum Creatinine: normal + Total: normal\n",
      "      313 patients (14.4%)\n",
      "   ğŸ“Š TSH: abnormal + Serum Creatinine: abnormal + Total: normal\n",
      "      171 patients (7.9%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 1,053 (48.5%)\n",
      "   Two or More Tests Abnormal: 171 (7.9%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: TSH + Total Serum Bilirubin + Blood Glucose\n",
      "ğŸ“Š Total Patients: 2,036\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ TSH:\n",
      "   Total Records: 2,411\n",
      "   âœ… Normal: 1,759 (73.0%)\n",
      "   âŒ Abnormal: 652 (27.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,765 (73.2%)\n",
      "      Male: 646 (26.8%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 2,339 (97.0%)\n",
      "      Biolab: 72 (3.0%)\n",
      "\n",
      "ğŸ“‹ Total Serum Bilirubin:\n",
      "   Total Records: 2,233\n",
      "   âœ… Normal: 2,233 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,574 (70.5%)\n",
      "      Male: 659 (29.5%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 2,186 (97.9%)\n",
      "      Biolab: 47 (2.1%)\n",
      "\n",
      "ğŸ“‹ Blood Glucose:\n",
      "   Total Records: 2,381\n",
      "   âœ… Normal: 2,381 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,701 (71.4%)\n",
      "      Male: 680 (28.6%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 2,341 (98.3%)\n",
      "      Biolab: 40 (1.7%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (2036 patients):\n",
      "   ğŸ“Š TSH: normal + Total: normal + Blood Glucose: normal\n",
      "      1,589 patients (78.0%)\n",
      "   ğŸ“Š TSH: abnormal + Total: normal + Blood Glucose: normal\n",
      "      447 patients (22.0%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 1,589 (78.0%)\n",
      "   Two or More Tests Abnormal: 0 (0.0%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Serum Cholesterol + Serum Triglycerides + Serum LDL Cholesterol\n",
      "ğŸ“Š Total Patients: 1,884\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Serum Cholesterol:\n",
      "   Total Records: 2,739\n",
      "   âœ… Normal: 2,738 (100.0%)\n",
      "   âŒ Abnormal: 1 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Male: 1,644 (60.0%)\n",
      "      Female: 1,095 (40.0%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Biolab: 2,739 (100.0%)\n",
      "\n",
      "ğŸ“‹ Serum Triglycerides:\n",
      "   Total Records: 2,777\n",
      "   âœ… Normal: 1,180 (42.5%)\n",
      "   âŒ Abnormal: 1,597 (57.5%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Male: 1,676 (60.4%)\n",
      "      Female: 1,101 (39.6%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Biolab: 2,777 (100.0%)\n",
      "\n",
      "ğŸ“‹ Serum LDL Cholesterol:\n",
      "   Total Records: 2,500\n",
      "   âœ… Normal: 784 (31.4%)\n",
      "   âŒ Abnormal: 1,716 (68.6%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Male: 1,492 (59.7%)\n",
      "      Female: 1,008 (40.3%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Biolab: 2,500 (100.0%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1884 patients):\n",
      "   ğŸ“Š Serum Cholesterol: normal + Serum Triglycerides: abnormal + Serum: abnormal\n",
      "      754 patients (40.0%)\n",
      "   ğŸ“Š Serum Cholesterol: normal + Serum Triglycerides: normal + Serum: abnormal\n",
      "      528 patients (28.0%)\n",
      "   ğŸ“Š Serum Cholesterol: normal + Serum Triglycerides: normal + Serum: normal\n",
      "      370 patients (19.6%)\n",
      "   ğŸ“Š Serum Cholesterol: normal + Serum Triglycerides: abnormal + Serum: normal\n",
      "      231 patients (12.3%)\n",
      "   ğŸ“Š Serum Cholesterol: abnormal + Serum Triglycerides: abnormal + Serum: normal\n",
      "      1 patients (0.1%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 370 (19.6%)\n",
      "   Two or More Tests Abnormal: 755 (40.1%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Serum Creatinine + Blood Glucose + C-Reactive Protein Titer\n",
      "ğŸ“Š Total Patients: 1,703\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Serum Creatinine:\n",
      "   Total Records: 2,323\n",
      "   âœ… Normal: 1,492 (64.2%)\n",
      "   âŒ Abnormal: 831 (35.8%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,473 (63.4%)\n",
      "      Male: 850 (36.6%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 2,096 (90.2%)\n",
      "      Biolab: 227 (9.8%)\n",
      "\n",
      "ğŸ“‹ Blood Glucose:\n",
      "   Total Records: 2,192\n",
      "   âœ… Normal: 2,192 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,429 (65.2%)\n",
      "      Male: 763 (34.8%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 2,053 (93.7%)\n",
      "      Biolab: 139 (6.3%)\n",
      "\n",
      "ğŸ“‹ C-Reactive Protein Titer:\n",
      "   Total Records: 2,163\n",
      "   âœ… Normal: 2,163 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,403 (64.9%)\n",
      "      Male: 760 (35.1%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,987 (91.9%)\n",
      "      Biolab: 176 (8.1%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1703 patients):\n",
      "   ğŸ“Š Serum Creatinine: normal + Blood Glucose: normal + C-Reactive: normal\n",
      "      1,117 patients (65.6%)\n",
      "   ğŸ“Š Serum Creatinine: abnormal + Blood Glucose: normal + C-Reactive: normal\n",
      "      586 patients (34.4%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 1,117 (65.6%)\n",
      "   Two or More Tests Abnormal: 0 (0.0%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Serum Cholesterol + Serum HDL Cholesterol + Serum LDL Cholesterol\n",
      "ğŸ“Š Total Patients: 1,579\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Serum Cholesterol:\n",
      "   Total Records: 2,325\n",
      "   âœ… Normal: 2,324 (100.0%)\n",
      "   âŒ Abnormal: 1 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Male: 1,416 (60.9%)\n",
      "      Female: 909 (39.1%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Biolab: 2,325 (100.0%)\n",
      "\n",
      "ğŸ“‹ Serum HDL Cholesterol:\n",
      "   Total Records: 1,997\n",
      "   âœ… Normal: 1,241 (62.1%)\n",
      "   âŒ Abnormal: 756 (37.9%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Male: 1,193 (59.7%)\n",
      "      Female: 804 (40.3%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Biolab: 1,997 (100.0%)\n",
      "\n",
      "ğŸ“‹ Serum LDL Cholesterol:\n",
      "   Total Records: 2,142\n",
      "   âœ… Normal: 668 (31.2%)\n",
      "   âŒ Abnormal: 1,474 (68.8%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Male: 1,301 (60.7%)\n",
      "      Female: 841 (39.3%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Biolab: 2,142 (100.0%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1579 patients):\n",
      "   ğŸ“Š Serum Cholesterol: normal + Serum: normal + Serum: abnormal\n",
      "      702 patients (44.5%)\n",
      "   ğŸ“Š Serum Cholesterol: normal + Serum: abnormal + Serum: abnormal\n",
      "      374 patients (23.7%)\n",
      "   ğŸ“Š Serum Cholesterol: normal + Serum: normal + Serum: normal\n",
      "      301 patients (19.1%)\n",
      "   ğŸ“Š Serum Cholesterol: normal + Serum: abnormal + Serum: normal\n",
      "      201 patients (12.7%)\n",
      "   ğŸ“Š Serum Cholesterol: abnormal + Serum: abnormal + Serum: normal\n",
      "      1 patients (0.1%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 301 (19.1%)\n",
      "   Two or More Tests Abnormal: 375 (23.7%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Serum Triglycerides + Serum HDL Cholesterol + Serum LDL Cholesterol\n",
      "ğŸ“Š Total Patients: 1,573\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Serum Triglycerides:\n",
      "   Total Records: 2,345\n",
      "   âœ… Normal: 1,005 (42.9%)\n",
      "   âŒ Abnormal: 1,340 (57.1%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Male: 1,432 (61.1%)\n",
      "      Female: 913 (38.9%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Biolab: 2,345 (100.0%)\n",
      "\n",
      "ğŸ“‹ Serum HDL Cholesterol:\n",
      "   Total Records: 1,991\n",
      "   âœ… Normal: 1,235 (62.0%)\n",
      "   âŒ Abnormal: 756 (38.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Male: 1,187 (59.6%)\n",
      "      Female: 804 (40.4%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Biolab: 1,991 (100.0%)\n",
      "\n",
      "ğŸ“‹ Serum LDL Cholesterol:\n",
      "   Total Records: 2,134\n",
      "   âœ… Normal: 670 (31.4%)\n",
      "   âŒ Abnormal: 1,464 (68.6%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Male: 1,293 (60.6%)\n",
      "      Female: 841 (39.4%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Biolab: 2,134 (100.0%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1573 patients):\n",
      "   ğŸ“Š Serum Triglycerides: normal + Serum: normal + Serum: abnormal\n",
      "      356 patients (22.6%)\n",
      "   ğŸ“Š Serum Triglycerides: abnormal + Serum: normal + Serum: abnormal\n",
      "      340 patients (21.6%)\n",
      "   ğŸ“Š Serum Triglycerides: abnormal + Serum: abnormal + Serum: abnormal\n",
      "      292 patients (18.6%)\n",
      "   ğŸ“Š Serum Triglycerides: normal + Serum: normal + Serum: normal\n",
      "      232 patients (14.7%)\n",
      "   ğŸ“Š Serum Triglycerides: abnormal + Serum: abnormal + Serum: normal\n",
      "      116 patients (7.4%)\n",
      "   ğŸ“Š Serum Triglycerides: normal + Serum: abnormal + Serum: normal\n",
      "      88 patients (5.6%)\n",
      "   ğŸ“Š Serum Triglycerides: normal + Serum: abnormal + Serum: abnormal\n",
      "      80 patients (5.1%)\n",
      "   ğŸ“Š Serum Triglycerides: abnormal + Serum: normal + Serum: normal\n",
      "      69 patients (4.4%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 232 (14.7%)\n",
      "   Two or More Tests Abnormal: 828 (52.6%)\n",
      "   All Three Tests Abnormal: 292 (18.6%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Serum Cholesterol + Serum Triglycerides + Serum HDL Cholesterol\n",
      "ğŸ“Š Total Patients: 1,572\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Serum Cholesterol:\n",
      "   Total Records: 2,322\n",
      "   âœ… Normal: 2,321 (100.0%)\n",
      "   âŒ Abnormal: 1 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Male: 1,415 (60.9%)\n",
      "      Female: 907 (39.1%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Biolab: 2,322 (100.0%)\n",
      "\n",
      "ğŸ“‹ Serum Triglycerides:\n",
      "   Total Records: 2,347\n",
      "   âœ… Normal: 1,005 (42.8%)\n",
      "   âŒ Abnormal: 1,342 (57.2%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Male: 1,436 (61.2%)\n",
      "      Female: 911 (38.8%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Biolab: 2,347 (100.0%)\n",
      "\n",
      "ğŸ“‹ Serum HDL Cholesterol:\n",
      "   Total Records: 1,990\n",
      "   âœ… Normal: 1,232 (61.9%)\n",
      "   âŒ Abnormal: 758 (38.1%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Male: 1,188 (59.7%)\n",
      "      Female: 802 (40.3%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Biolab: 1,990 (100.0%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1572 patients):\n",
      "   ğŸ“Š Serum Cholesterol: normal + Serum Triglycerides: normal + Serum: normal\n",
      "      587 patients (37.3%)\n",
      "   ğŸ“Š Serum Cholesterol: normal + Serum Triglycerides: abnormal + Serum: abnormal\n",
      "      409 patients (26.0%)\n",
      "   ğŸ“Š Serum Cholesterol: normal + Serum Triglycerides: abnormal + Serum: normal\n",
      "      407 patients (25.9%)\n",
      "   ğŸ“Š Serum Cholesterol: normal + Serum Triglycerides: normal + Serum: abnormal\n",
      "      168 patients (10.7%)\n",
      "   ğŸ“Š Serum Cholesterol: abnormal + Serum Triglycerides: abnormal + Serum: abnormal\n",
      "      1 patients (0.1%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 587 (37.3%)\n",
      "   Two or More Tests Abnormal: 410 (26.1%)\n",
      "   All Three Tests Abnormal: 1 (0.1%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Serum Creatinine + Aspartate Aminotransferase (AST) + Alanine Aminotransferase (ALT)\n",
      "ğŸ“Š Total Patients: 1,354\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Serum Creatinine:\n",
      "   Total Records: 1,836\n",
      "   âœ… Normal: 1,305 (71.1%)\n",
      "   âŒ Abnormal: 531 (28.9%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Male: 929 (50.6%)\n",
      "      Female: 907 (49.4%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 964 (52.5%)\n",
      "      Biolab: 872 (47.5%)\n",
      "\n",
      "ğŸ“‹ Aspartate Aminotransferase (AST):\n",
      "   Total Records: 1,585\n",
      "   âœ… Normal: 1,412 (89.1%)\n",
      "   âŒ Abnormal: 173 (10.9%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Male: 799 (50.4%)\n",
      "      Female: 786 (49.6%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 815 (51.4%)\n",
      "      Biolab: 770 (48.6%)\n",
      "\n",
      "ğŸ“‹ Alanine Aminotransferase (ALT):\n",
      "   Total Records: 1,598\n",
      "   âœ… Normal: 1,446 (90.5%)\n",
      "   âŒ Abnormal: 152 (9.5%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Male: 806 (50.4%)\n",
      "      Female: 792 (49.6%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 822 (51.4%)\n",
      "      Biolab: 776 (48.6%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1354 patients):\n",
      "   ğŸ“Š Serum Creatinine: normal + Aspartate: normal + Alanine: normal\n",
      "      849 patients (62.7%)\n",
      "   ğŸ“Š Serum Creatinine: abnormal + Aspartate: normal + Alanine: normal\n",
      "      338 patients (25.0%)\n",
      "   ğŸ“Š Serum Creatinine: normal + Aspartate: normal + Alanine: abnormal\n",
      "      38 patients (2.8%)\n",
      "   ğŸ“Š Serum Creatinine: normal + Aspartate: abnormal + Alanine: abnormal\n",
      "      33 patients (2.4%)\n",
      "   ğŸ“Š Serum Creatinine: normal + Aspartate: abnormal + Alanine: normal\n",
      "      33 patients (2.4%)\n",
      "   ğŸ“Š Serum Creatinine: abnormal + Aspartate: abnormal + Alanine: normal\n",
      "      33 patients (2.4%)\n",
      "   ğŸ“Š Serum Creatinine: abnormal + Aspartate: abnormal + Alanine: abnormal\n",
      "      23 patients (1.7%)\n",
      "   ğŸ“Š Serum Creatinine: abnormal + Aspartate: normal + Alanine: abnormal\n",
      "      7 patients (0.5%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 849 (62.7%)\n",
      "   Two or More Tests Abnormal: 96 (7.1%)\n",
      "   All Three Tests Abnormal: 23 (1.7%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: HbA1c + Serum Creatinine + Blood Glucose\n",
      "ğŸ“Š Total Patients: 1,208\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ HbA1c:\n",
      "   Total Records: 1,788\n",
      "   âœ… Normal: 271 (15.2%)\n",
      "   âŒ Abnormal: 1,517 (84.8%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,187 (66.4%)\n",
      "      Male: 601 (33.6%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,451 (81.2%)\n",
      "      Biolab: 337 (18.8%)\n",
      "\n",
      "ğŸ“‹ Serum Creatinine:\n",
      "   Total Records: 1,747\n",
      "   âœ… Normal: 1,124 (64.3%)\n",
      "   âŒ Abnormal: 623 (35.7%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,156 (66.2%)\n",
      "      Male: 591 (33.8%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,453 (83.2%)\n",
      "      Biolab: 294 (16.8%)\n",
      "\n",
      "ğŸ“‹ Blood Glucose:\n",
      "   Total Records: 1,732\n",
      "   âœ… Normal: 1,732 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,172 (67.7%)\n",
      "      Male: 560 (32.3%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,509 (87.1%)\n",
      "      Biolab: 223 (12.9%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1208 patients):\n",
      "   ğŸ“Š HbA1c: abnormal + Serum Creatinine: normal + Blood Glucose: normal\n",
      "      638 patients (52.8%)\n",
      "   ğŸ“Š HbA1c: abnormal + Serum Creatinine: abnormal + Blood Glucose: normal\n",
      "      354 patients (29.3%)\n",
      "   ğŸ“Š HbA1c: normal + Serum Creatinine: normal + Blood Glucose: normal\n",
      "      143 patients (11.8%)\n",
      "   ğŸ“Š HbA1c: normal + Serum Creatinine: abnormal + Blood Glucose: normal\n",
      "      73 patients (6.0%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 143 (11.8%)\n",
      "   Two or More Tests Abnormal: 354 (29.3%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Total Cholesterol + Triglycerides + LDL Cholesterol\n",
      "ğŸ“Š Total Patients: 1,120\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Total Cholesterol:\n",
      "   Total Records: 1,217\n",
      "   âœ… Normal: 936 (76.9%)\n",
      "   âŒ Abnormal: 281 (23.1%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 713 (58.6%)\n",
      "      Male: 504 (41.4%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,070 (87.9%)\n",
      "      Darugha: 147 (12.1%)\n",
      "\n",
      "ğŸ“‹ Triglycerides:\n",
      "   Total Records: 1,197\n",
      "   âœ… Normal: 496 (41.4%)\n",
      "   âŒ Abnormal: 701 (58.6%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 705 (58.9%)\n",
      "      Male: 492 (41.1%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,050 (87.7%)\n",
      "      Darugha: 147 (12.3%)\n",
      "\n",
      "ğŸ“‹ LDL Cholesterol:\n",
      "   Total Records: 1,240\n",
      "   âœ… Normal: 1,240 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 733 (59.1%)\n",
      "      Male: 507 (40.9%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,093 (88.1%)\n",
      "      Darugha: 147 (11.9%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1120 patients):\n",
      "   ğŸ“Š Total Cholesterol: normal + Triglycerides: abnormal + LDL Cholesterol: normal\n",
      "      484 patients (43.2%)\n",
      "   ğŸ“Š Total Cholesterol: normal + Triglycerides: normal + LDL Cholesterol: normal\n",
      "      387 patients (34.6%)\n",
      "   ğŸ“Š Total Cholesterol: abnormal + Triglycerides: abnormal + LDL Cholesterol: normal\n",
      "      174 patients (15.5%)\n",
      "   ğŸ“Š Total Cholesterol: abnormal + Triglycerides: normal + LDL Cholesterol: normal\n",
      "      75 patients (6.7%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 387 (34.6%)\n",
      "   Two or More Tests Abnormal: 174 (15.5%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Aspartate Aminotransferase (AST) + Alanine Aminotransferase (ALT) + Alkaline Phosphatase\n",
      "ğŸ“Š Total Patients: 1,111\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Aspartate Aminotransferase (AST):\n",
      "   Total Records: 1,276\n",
      "   âœ… Normal: 1,100 (86.2%)\n",
      "   âŒ Abnormal: 176 (13.8%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 720 (56.4%)\n",
      "      Male: 556 (43.6%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 936 (73.4%)\n",
      "      Biolab: 338 (26.5%)\n",
      "      Darugha: 2 (0.2%)\n",
      "\n",
      "ğŸ“‹ Alanine Aminotransferase (ALT):\n",
      "   Total Records: 1,277\n",
      "   âœ… Normal: 1,119 (87.6%)\n",
      "   âŒ Abnormal: 158 (12.4%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 720 (56.4%)\n",
      "      Male: 557 (43.6%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 937 (73.4%)\n",
      "      Biolab: 338 (26.5%)\n",
      "      Darugha: 2 (0.2%)\n",
      "\n",
      "ğŸ“‹ Alkaline Phosphatase:\n",
      "   Total Records: 1,246\n",
      "   âœ… Normal: 1,053 (84.5%)\n",
      "   âŒ Abnormal: 193 (15.5%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 708 (56.8%)\n",
      "      Male: 538 (43.2%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 932 (74.8%)\n",
      "      Biolab: 312 (25.0%)\n",
      "      Darugha: 2 (0.2%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1111 patients):\n",
      "   ğŸ“Š Aspartate: normal + Alanine: normal + Alkaline Phosphatase: normal\n",
      "      833 patients (75.0%)\n",
      "   ğŸ“Š Aspartate: normal + Alanine: normal + Alkaline Phosphatase: abnormal\n",
      "      105 patients (9.5%)\n",
      "   ğŸ“Š Aspartate: abnormal + Alanine: abnormal + Alkaline Phosphatase: normal\n",
      "      46 patients (4.1%)\n",
      "   ğŸ“Š Aspartate: normal + Alanine: abnormal + Alkaline Phosphatase: normal\n",
      "      40 patients (3.6%)\n",
      "   ğŸ“Š Aspartate: abnormal + Alanine: normal + Alkaline Phosphatase: normal\n",
      "      34 patients (3.1%)\n",
      "   ğŸ“Š Aspartate: abnormal + Alanine: abnormal + Alkaline Phosphatase: abnormal\n",
      "      26 patients (2.3%)\n",
      "   ğŸ“Š Aspartate: abnormal + Alanine: normal + Alkaline Phosphatase: abnormal\n",
      "      23 patients (2.1%)\n",
      "   ğŸ“Š Aspartate: normal + Alanine: abnormal + Alkaline Phosphatase: abnormal\n",
      "      4 patients (0.4%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 833 (75.0%)\n",
      "   Two or More Tests Abnormal: 99 (8.9%)\n",
      "   All Three Tests Abnormal: 26 (2.3%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Serum Creatinine + Serum Ferritin + Blood Glucose\n",
      "ğŸ“Š Total Patients: 1,101\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Serum Creatinine:\n",
      "   Total Records: 1,405\n",
      "   âœ… Normal: 775 (55.2%)\n",
      "   âŒ Abnormal: 630 (44.8%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,123 (79.9%)\n",
      "      Male: 282 (20.1%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,304 (92.8%)\n",
      "      Biolab: 101 (7.2%)\n",
      "\n",
      "ğŸ“‹ Serum Ferritin:\n",
      "   Total Records: 1,281\n",
      "   âœ… Normal: 995 (77.7%)\n",
      "   âŒ Abnormal: 286 (22.3%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,044 (81.5%)\n",
      "      Male: 237 (18.5%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,221 (95.3%)\n",
      "      Biolab: 60 (4.7%)\n",
      "\n",
      "ğŸ“‹ Blood Glucose:\n",
      "   Total Records: 1,354\n",
      "   âœ… Normal: 1,354 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,097 (81.0%)\n",
      "      Male: 257 (19.0%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,288 (95.1%)\n",
      "      Biolab: 66 (4.9%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1101 patients):\n",
      "   ğŸ“Š Serum Creatinine: normal + Serum Ferritin: normal + Blood Glucose: normal\n",
      "      494 patients (44.9%)\n",
      "   ğŸ“Š Serum Creatinine: abnormal + Serum Ferritin: normal + Blood Glucose: normal\n",
      "      380 patients (34.5%)\n",
      "   ğŸ“Š Serum Creatinine: normal + Serum Ferritin: abnormal + Blood Glucose: normal\n",
      "      121 patients (11.0%)\n",
      "   ğŸ“Š Serum Creatinine: abnormal + Serum Ferritin: abnormal + Blood Glucose: normal\n",
      "      106 patients (9.6%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 494 (44.9%)\n",
      "   Two or More Tests Abnormal: 106 (9.6%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Serum Creatinine + Blood Glucose + LDL Cholesterol\n",
      "ğŸ“Š Total Patients: 1,088\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Serum Creatinine:\n",
      "   Total Records: 1,350\n",
      "   âœ… Normal: 970 (71.9%)\n",
      "   âŒ Abnormal: 380 (28.1%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 841 (62.3%)\n",
      "      Male: 509 (37.7%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,346 (99.7%)\n",
      "      Biolab: 4 (0.3%)\n",
      "\n",
      "ğŸ“‹ Blood Glucose:\n",
      "   Total Records: 1,343\n",
      "   âœ… Normal: 1,343 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 838 (62.4%)\n",
      "      Male: 505 (37.6%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,341 (99.9%)\n",
      "      Biolab: 2 (0.1%)\n",
      "\n",
      "ğŸ“‹ LDL Cholesterol:\n",
      "   Total Records: 1,218\n",
      "   âœ… Normal: 1,218 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 754 (61.9%)\n",
      "      Male: 464 (38.1%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,218 (100.0%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1088 patients):\n",
      "   ğŸ“Š Serum Creatinine: normal + Blood Glucose: normal + LDL Cholesterol: normal\n",
      "      786 patients (72.2%)\n",
      "   ğŸ“Š Serum Creatinine: abnormal + Blood Glucose: normal + LDL Cholesterol: normal\n",
      "      302 patients (27.8%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 786 (72.2%)\n",
      "   Two or More Tests Abnormal: 0 (0.0%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Serum Creatinine + Total Serum Bilirubin + C-Reactive Protein Titer\n",
      "ğŸ“Š Total Patients: 1,072\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Serum Creatinine:\n",
      "   Total Records: 1,511\n",
      "   âœ… Normal: 950 (62.9%)\n",
      "   âŒ Abnormal: 561 (37.1%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 990 (65.5%)\n",
      "      Male: 521 (34.5%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,393 (92.2%)\n",
      "      Biolab: 118 (7.8%)\n",
      "\n",
      "ğŸ“‹ Total Serum Bilirubin:\n",
      "   Total Records: 1,268\n",
      "   âœ… Normal: 1,268 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 811 (64.0%)\n",
      "      Male: 457 (36.0%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,197 (94.4%)\n",
      "      Biolab: 71 (5.6%)\n",
      "\n",
      "ğŸ“‹ C-Reactive Protein Titer:\n",
      "   Total Records: 1,408\n",
      "   âœ… Normal: 1,408 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 920 (65.3%)\n",
      "      Male: 488 (34.7%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,314 (93.3%)\n",
      "      Biolab: 94 (6.7%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1072 patients):\n",
      "   ğŸ“Š Serum Creatinine: normal + Total: normal + C-Reactive: normal\n",
      "      700 patients (65.3%)\n",
      "   ğŸ“Š Serum Creatinine: abnormal + Total: normal + C-Reactive: normal\n",
      "      372 patients (34.7%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 700 (65.3%)\n",
      "   Two or More Tests Abnormal: 0 (0.0%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Aspartate Aminotransferase (AST) + Alanine Aminotransferase (ALT) + Total Serum Bilirubin\n",
      "ğŸ“Š Total Patients: 1,060\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Aspartate Aminotransferase (AST):\n",
      "   Total Records: 1,236\n",
      "   âœ… Normal: 1,059 (85.7%)\n",
      "   âŒ Abnormal: 177 (14.3%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 713 (57.7%)\n",
      "      Male: 523 (42.3%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 980 (79.3%)\n",
      "      Biolab: 253 (20.5%)\n",
      "      Darugha: 3 (0.2%)\n",
      "\n",
      "ğŸ“‹ Alanine Aminotransferase (ALT):\n",
      "   Total Records: 1,242\n",
      "   âœ… Normal: 1,092 (87.9%)\n",
      "   âŒ Abnormal: 150 (12.1%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 720 (58.0%)\n",
      "      Male: 522 (42.0%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 988 (79.5%)\n",
      "      Biolab: 251 (20.2%)\n",
      "      Darugha: 3 (0.2%)\n",
      "\n",
      "ğŸ“‹ Total Serum Bilirubin:\n",
      "   Total Records: 1,346\n",
      "   âœ… Normal: 1,346 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 769 (57.1%)\n",
      "      Male: 577 (42.9%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,098 (81.6%)\n",
      "      Biolab: 245 (18.2%)\n",
      "      Darugha: 3 (0.2%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1060 patients):\n",
      "   ğŸ“Š Aspartate: normal + Alanine: normal + Total: normal\n",
      "      893 patients (84.2%)\n",
      "   ğŸ“Š Aspartate: abnormal + Alanine: abnormal + Total: normal\n",
      "      70 patients (6.6%)\n",
      "   ğŸ“Š Aspartate: abnormal + Alanine: normal + Total: normal\n",
      "      59 patients (5.6%)\n",
      "   ğŸ“Š Aspartate: normal + Alanine: abnormal + Total: normal\n",
      "      38 patients (3.6%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 893 (84.2%)\n",
      "   Two or More Tests Abnormal: 70 (6.6%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: TSH + Total Cholesterol + LDL Cholesterol\n",
      "ğŸ“Š Total Patients: 1,048\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ TSH:\n",
      "   Total Records: 1,208\n",
      "   âœ… Normal: 899 (74.4%)\n",
      "   âŒ Abnormal: 309 (25.6%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 787 (65.1%)\n",
      "      Male: 421 (34.9%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,134 (93.9%)\n",
      "      Darugha: 70 (5.8%)\n",
      "      Biolab: 4 (0.3%)\n",
      "\n",
      "ğŸ“‹ Total Cholesterol:\n",
      "   Total Records: 1,122\n",
      "   âœ… Normal: 864 (77.0%)\n",
      "   âŒ Abnormal: 258 (23.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 702 (62.6%)\n",
      "      Male: 420 (37.4%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,052 (93.8%)\n",
      "      Darugha: 70 (6.2%)\n",
      "\n",
      "ğŸ“‹ LDL Cholesterol:\n",
      "   Total Records: 1,152\n",
      "   âœ… Normal: 1,152 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 724 (62.8%)\n",
      "      Male: 428 (37.2%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,082 (93.9%)\n",
      "      Darugha: 70 (6.1%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1048 patients):\n",
      "   ğŸ“Š TSH: normal + Total Cholesterol: normal + LDL Cholesterol: normal\n",
      "      647 patients (61.7%)\n",
      "   ğŸ“Š TSH: normal + Total Cholesterol: abnormal + LDL Cholesterol: normal\n",
      "      178 patients (17.0%)\n",
      "   ğŸ“Š TSH: abnormal + Total Cholesterol: normal + LDL Cholesterol: normal\n",
      "      170 patients (16.2%)\n",
      "   ğŸ“Š TSH: abnormal + Total Cholesterol: abnormal + LDL Cholesterol: normal\n",
      "      53 patients (5.1%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 647 (61.7%)\n",
      "   Two or More Tests Abnormal: 53 (5.1%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Blood Glucose + Total Cholesterol + LDL Cholesterol\n",
      "ğŸ“Š Total Patients: 1,041\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Blood Glucose:\n",
      "   Total Records: 1,267\n",
      "   âœ… Normal: 1,267 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 752 (59.4%)\n",
      "      Male: 515 (40.6%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,265 (99.8%)\n",
      "      Biolab: 2 (0.2%)\n",
      "\n",
      "ğŸ“‹ Total Cholesterol:\n",
      "   Total Records: 1,130\n",
      "   âœ… Normal: 882 (78.1%)\n",
      "   âŒ Abnormal: 248 (21.9%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 665 (58.8%)\n",
      "      Male: 465 (41.2%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,130 (100.0%)\n",
      "\n",
      "ğŸ“‹ LDL Cholesterol:\n",
      "   Total Records: 1,168\n",
      "   âœ… Normal: 1,168 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 692 (59.2%)\n",
      "      Male: 476 (40.8%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,168 (100.0%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1041 patients):\n",
      "   ğŸ“Š Blood Glucose: normal + Total Cholesterol: normal + LDL Cholesterol: normal\n",
      "      821 patients (78.9%)\n",
      "   ğŸ“Š Blood Glucose: normal + Total Cholesterol: abnormal + LDL Cholesterol: normal\n",
      "      220 patients (21.1%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 821 (78.9%)\n",
      "   Two or More Tests Abnormal: 0 (0.0%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: TSH + Serum Creatinine + Serum Ferritin\n",
      "ğŸ“Š Total Patients: 1,039\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ TSH:\n",
      "   Total Records: 1,402\n",
      "   âœ… Normal: 948 (67.6%)\n",
      "   âŒ Abnormal: 454 (32.4%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,162 (82.9%)\n",
      "      Male: 240 (17.1%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,213 (86.5%)\n",
      "      Biolab: 189 (13.5%)\n",
      "\n",
      "ğŸ“‹ Serum Creatinine:\n",
      "   Total Records: 1,263\n",
      "   âœ… Normal: 708 (56.1%)\n",
      "   âŒ Abnormal: 555 (43.9%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,026 (81.2%)\n",
      "      Male: 237 (18.8%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,123 (88.9%)\n",
      "      Biolab: 140 (11.1%)\n",
      "\n",
      "ğŸ“‹ Serum Ferritin:\n",
      "   Total Records: 1,218\n",
      "   âœ… Normal: 948 (77.8%)\n",
      "   âŒ Abnormal: 270 (22.2%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 998 (81.9%)\n",
      "      Male: 220 (18.1%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,092 (89.7%)\n",
      "      Biolab: 126 (10.3%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1039 patients):\n",
      "   ğŸ“Š TSH: normal + Serum Creatinine: normal + Serum Ferritin: normal\n",
      "      353 patients (34.0%)\n",
      "   ğŸ“Š TSH: normal + Serum Creatinine: abnormal + Serum Ferritin: normal\n",
      "      275 patients (26.5%)\n",
      "   ğŸ“Š TSH: abnormal + Serum Creatinine: normal + Serum Ferritin: normal\n",
      "      117 patients (11.3%)\n",
      "   ğŸ“Š TSH: abnormal + Serum Creatinine: abnormal + Serum Ferritin: normal\n",
      "      89 patients (8.6%)\n",
      "   ğŸ“Š TSH: normal + Serum Creatinine: normal + Serum Ferritin: abnormal\n",
      "      84 patients (8.1%)\n",
      "   ğŸ“Š TSH: normal + Serum Creatinine: abnormal + Serum Ferritin: abnormal\n",
      "      74 patients (7.1%)\n",
      "   ğŸ“Š TSH: abnormal + Serum Creatinine: normal + Serum Ferritin: abnormal\n",
      "      27 patients (2.6%)\n",
      "   ğŸ“Š TSH: abnormal + Serum Creatinine: abnormal + Serum Ferritin: abnormal\n",
      "      20 patients (1.9%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 353 (34.0%)\n",
      "   Two or More Tests Abnormal: 210 (20.2%)\n",
      "   All Three Tests Abnormal: 20 (1.9%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Hepatitis B Surface Antigen + Hepatitis C Antibody + Blood Glucose\n",
      "ğŸ“Š Total Patients: 1,035\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Hepatitis B Surface Antigen:\n",
      "   Total Records: 1,100\n",
      "   âœ… Normal: 1,099 (99.9%)\n",
      "   âŒ Abnormal: 1 (0.1%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 742 (67.5%)\n",
      "      Male: 358 (32.5%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 659 (59.9%)\n",
      "      Biolab: 441 (40.1%)\n",
      "\n",
      "ğŸ“‹ Hepatitis C Antibody:\n",
      "   Total Records: 1,098\n",
      "   âœ… Normal: 1,098 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 741 (67.5%)\n",
      "      Male: 357 (32.5%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 658 (59.9%)\n",
      "      Biolab: 440 (40.1%)\n",
      "\n",
      "ğŸ“‹ Blood Glucose:\n",
      "   Total Records: 1,316\n",
      "   âœ… Normal: 1,316 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 924 (70.2%)\n",
      "      Male: 392 (29.8%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 839 (63.8%)\n",
      "      Biolab: 477 (36.2%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1035 patients):\n",
      "   ğŸ“Š Hepatitis: normal + Hepatitis: normal + Blood Glucose: normal\n",
      "      1,034 patients (99.9%)\n",
      "   ğŸ“Š Hepatitis: abnormal + Hepatitis: normal + Blood Glucose: normal\n",
      "      1 patients (0.1%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 1,034 (99.9%)\n",
      "   Two or More Tests Abnormal: 0 (0.0%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Hepatitis B Surface Antigen + HIV Antibody + Blood Glucose\n",
      "ğŸ“Š Total Patients: 1,034\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Hepatitis B Surface Antigen:\n",
      "   Total Records: 1,099\n",
      "   âœ… Normal: 1,098 (99.9%)\n",
      "   âŒ Abnormal: 1 (0.1%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 741 (67.4%)\n",
      "      Male: 358 (32.6%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 659 (60.0%)\n",
      "      Biolab: 440 (40.0%)\n",
      "\n",
      "ğŸ“‹ HIV Antibody:\n",
      "   Total Records: 1,097\n",
      "   âœ… Normal: 1,097 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 740 (67.5%)\n",
      "      Male: 357 (32.5%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 658 (60.0%)\n",
      "      Biolab: 439 (40.0%)\n",
      "\n",
      "ğŸ“‹ Blood Glucose:\n",
      "   Total Records: 1,315\n",
      "   âœ… Normal: 1,315 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 923 (70.2%)\n",
      "      Male: 392 (29.8%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 839 (63.8%)\n",
      "      Biolab: 476 (36.2%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1034 patients):\n",
      "   ğŸ“Š Hepatitis: normal + HIV Antibody: normal + Blood Glucose: normal\n",
      "      1,033 patients (99.9%)\n",
      "   ğŸ“Š Hepatitis: abnormal + HIV Antibody: normal + Blood Glucose: normal\n",
      "      1 patients (0.1%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 1,033 (99.9%)\n",
      "   Two or More Tests Abnormal: 0 (0.0%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Hepatitis C Antibody + HIV Antibody + Blood Glucose\n",
      "ğŸ“Š Total Patients: 1,034\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Hepatitis C Antibody:\n",
      "   Total Records: 1,097\n",
      "   âœ… Normal: 1,097 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 740 (67.5%)\n",
      "      Male: 357 (32.5%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 658 (60.0%)\n",
      "      Biolab: 439 (40.0%)\n",
      "\n",
      "ğŸ“‹ HIV Antibody:\n",
      "   Total Records: 1,097\n",
      "   âœ… Normal: 1,097 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 740 (67.5%)\n",
      "      Male: 357 (32.5%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 658 (60.0%)\n",
      "      Biolab: 439 (40.0%)\n",
      "\n",
      "ğŸ“‹ Blood Glucose:\n",
      "   Total Records: 1,315\n",
      "   âœ… Normal: 1,315 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 923 (70.2%)\n",
      "      Male: 392 (29.8%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 839 (63.8%)\n",
      "      Biolab: 476 (36.2%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1034 patients):\n",
      "   ğŸ“Š Hepatitis: normal + HIV Antibody: normal + Blood Glucose: normal\n",
      "      1,034 patients (100.0%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 1,034 (100.0%)\n",
      "   Two or More Tests Abnormal: 0 (0.0%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Total Serum Bilirubin + Blood Glucose + C-Reactive Protein Titer\n",
      "ğŸ“Š Total Patients: 1,031\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Total Serum Bilirubin:\n",
      "   Total Records: 1,202\n",
      "   âœ… Normal: 1,202 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 789 (65.6%)\n",
      "      Male: 413 (34.4%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,178 (98.0%)\n",
      "      Biolab: 24 (2.0%)\n",
      "\n",
      "ğŸ“‹ Blood Glucose:\n",
      "   Total Records: 1,344\n",
      "   âœ… Normal: 1,344 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 914 (68.0%)\n",
      "      Male: 430 (32.0%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,320 (98.2%)\n",
      "      Biolab: 24 (1.8%)\n",
      "\n",
      "ğŸ“‹ C-Reactive Protein Titer:\n",
      "   Total Records: 1,339\n",
      "   âœ… Normal: 1,339 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 907 (67.7%)\n",
      "      Male: 432 (32.3%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,297 (96.9%)\n",
      "      Biolab: 42 (3.1%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1031 patients):\n",
      "   ğŸ“Š Total: normal + Blood Glucose: normal + C-Reactive: normal\n",
      "      1,031 patients (100.0%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 1,031 (100.0%)\n",
      "   Two or More Tests Abnormal: 0 (0.0%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: TSH + Serum Ferritin + Blood Glucose\n",
      "ğŸ“Š Total Patients: 1,027\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ TSH:\n",
      "   Total Records: 1,409\n",
      "   âœ… Normal: 996 (70.7%)\n",
      "   âŒ Abnormal: 413 (29.3%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,185 (84.1%)\n",
      "      Male: 224 (15.9%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,215 (86.2%)\n",
      "      Biolab: 194 (13.8%)\n",
      "\n",
      "ğŸ“‹ Serum Ferritin:\n",
      "   Total Records: 1,215\n",
      "   âœ… Normal: 951 (78.3%)\n",
      "   âŒ Abnormal: 264 (21.7%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,002 (82.5%)\n",
      "      Male: 213 (17.5%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,090 (89.7%)\n",
      "      Biolab: 125 (10.3%)\n",
      "\n",
      "ğŸ“‹ Blood Glucose:\n",
      "   Total Records: 1,241\n",
      "   âœ… Normal: 1,241 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 1,016 (81.9%)\n",
      "      Male: 225 (18.1%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,120 (90.2%)\n",
      "      Biolab: 121 (9.8%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1027 patients):\n",
      "   ğŸ“Š TSH: normal + Serum Ferritin: normal + Blood Glucose: normal\n",
      "      640 patients (62.3%)\n",
      "   ğŸ“Š TSH: abnormal + Serum Ferritin: normal + Blood Glucose: normal\n",
      "      185 patients (18.0%)\n",
      "   ğŸ“Š TSH: normal + Serum Ferritin: abnormal + Blood Glucose: normal\n",
      "      163 patients (15.9%)\n",
      "   ğŸ“Š TSH: abnormal + Serum Ferritin: abnormal + Blood Glucose: normal\n",
      "      39 patients (3.8%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 640 (62.3%)\n",
      "   Two or More Tests Abnormal: 39 (3.8%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Serum Creatinine + Total Cholesterol + LDL Cholesterol\n",
      "ğŸ“Š Total Patients: 1,024\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Serum Creatinine:\n",
      "   Total Records: 1,243\n",
      "   âœ… Normal: 895 (72.0%)\n",
      "   âŒ Abnormal: 348 (28.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 750 (60.3%)\n",
      "      Male: 493 (39.7%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,241 (99.8%)\n",
      "      Biolab: 2 (0.2%)\n",
      "\n",
      "ğŸ“‹ Total Cholesterol:\n",
      "   Total Records: 1,108\n",
      "   âœ… Normal: 853 (77.0%)\n",
      "   âŒ Abnormal: 255 (23.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 669 (60.4%)\n",
      "      Male: 439 (39.6%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,108 (100.0%)\n",
      "\n",
      "ğŸ“‹ LDL Cholesterol:\n",
      "   Total Records: 1,148\n",
      "   âœ… Normal: 1,148 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 698 (60.8%)\n",
      "      Male: 450 (39.2%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,148 (100.0%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1024 patients):\n",
      "   ğŸ“Š Serum Creatinine: normal + Total Cholesterol: normal + LDL Cholesterol: normal\n",
      "      578 patients (56.4%)\n",
      "   ğŸ“Š Serum Creatinine: abnormal + Total Cholesterol: normal + LDL Cholesterol: normal\n",
      "      219 patients (21.4%)\n",
      "   ğŸ“Š Serum Creatinine: normal + Total Cholesterol: abnormal + LDL Cholesterol: normal\n",
      "      158 patients (15.4%)\n",
      "   ğŸ“Š Serum Creatinine: abnormal + Total Cholesterol: abnormal + LDL Cholesterol: normal\n",
      "      69 patients (6.7%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 578 (56.4%)\n",
      "   Two or More Tests Abnormal: 69 (6.7%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: TSH + Serum Creatinine + C-Reactive Protein Titer\n",
      "ğŸ“Š Total Patients: 1,013\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ TSH:\n",
      "   Total Records: 1,334\n",
      "   âœ… Normal: 936 (70.2%)\n",
      "   âŒ Abnormal: 398 (29.8%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 925 (69.3%)\n",
      "      Male: 409 (30.7%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,067 (80.0%)\n",
      "      Biolab: 267 (20.0%)\n",
      "\n",
      "ğŸ“‹ Serum Creatinine:\n",
      "   Total Records: 1,432\n",
      "   âœ… Normal: 901 (62.9%)\n",
      "   âŒ Abnormal: 531 (37.1%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 954 (66.6%)\n",
      "      Male: 478 (33.4%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,174 (82.0%)\n",
      "      Biolab: 258 (18.0%)\n",
      "\n",
      "ğŸ“‹ C-Reactive Protein Titer:\n",
      "   Total Records: 1,312\n",
      "   âœ… Normal: 1,312 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 897 (68.4%)\n",
      "      Male: 415 (31.6%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,097 (83.6%)\n",
      "      Biolab: 215 (16.4%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1013 patients):\n",
      "   ğŸ“Š TSH: normal + Serum Creatinine: normal + C-Reactive: normal\n",
      "      503 patients (49.7%)\n",
      "   ğŸ“Š TSH: normal + Serum Creatinine: abnormal + C-Reactive: normal\n",
      "      274 patients (27.0%)\n",
      "   ğŸ“Š TSH: abnormal + Serum Creatinine: normal + C-Reactive: normal\n",
      "      138 patients (13.6%)\n",
      "   ğŸ“Š TSH: abnormal + Serum Creatinine: abnormal + C-Reactive: normal\n",
      "      98 patients (9.7%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 503 (49.7%)\n",
      "   Two or More Tests Abnormal: 98 (9.7%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: TSH + Serum Creatinine + LDL Cholesterol\n",
      "ğŸ“Š Total Patients: 1,004\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ TSH:\n",
      "   Total Records: 1,158\n",
      "   âœ… Normal: 871 (75.2%)\n",
      "   âŒ Abnormal: 287 (24.8%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 762 (65.8%)\n",
      "      Male: 396 (34.2%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,153 (99.6%)\n",
      "      Biolab: 5 (0.4%)\n",
      "\n",
      "ğŸ“‹ Serum Creatinine:\n",
      "   Total Records: 1,210\n",
      "   âœ… Normal: 854 (70.6%)\n",
      "   âŒ Abnormal: 356 (29.4%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 774 (64.0%)\n",
      "      Male: 436 (36.0%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,206 (99.7%)\n",
      "      Biolab: 4 (0.3%)\n",
      "\n",
      "ğŸ“‹ LDL Cholesterol:\n",
      "   Total Records: 1,107\n",
      "   âœ… Normal: 1,107 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 702 (63.4%)\n",
      "      Male: 405 (36.6%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,107 (100.0%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1004 patients):\n",
      "   ğŸ“Š TSH: normal + Serum Creatinine: normal + LDL Cholesterol: normal\n",
      "      559 patients (55.7%)\n",
      "   ğŸ“Š TSH: normal + Serum Creatinine: abnormal + LDL Cholesterol: normal\n",
      "      237 patients (23.6%)\n",
      "   ğŸ“Š TSH: abnormal + Serum Creatinine: normal + LDL Cholesterol: normal\n",
      "      152 patients (15.1%)\n",
      "   ğŸ“Š TSH: abnormal + Serum Creatinine: abnormal + LDL Cholesterol: normal\n",
      "      56 patients (5.6%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 559 (55.7%)\n",
      "   Two or More Tests Abnormal: 56 (5.6%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ§ª TEST COMBINATION: Blood Urea Nitrogen + Serum Creatinine + Blood Glucose\n",
      "ğŸ“Š Total Patients: 1,003\n",
      "--------------------------------------------------------------------------------\n",
      "\n",
      "ğŸ“‹ Blood Urea Nitrogen:\n",
      "   Total Records: 1,438\n",
      "   âœ… Normal: 388 (27.0%)\n",
      "   âŒ Abnormal: 1,050 (73.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 728 (50.6%)\n",
      "      Male: 710 (49.4%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 746 (51.9%)\n",
      "      Biolab: 692 (48.1%)\n",
      "\n",
      "ğŸ“‹ Serum Creatinine:\n",
      "   Total Records: 1,733\n",
      "   âœ… Normal: 1,141 (65.8%)\n",
      "   âŒ Abnormal: 592 (34.2%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 886 (51.1%)\n",
      "      Male: 847 (48.9%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 1,008 (58.2%)\n",
      "      Biolab: 725 (41.8%)\n",
      "\n",
      "ğŸ“‹ Blood Glucose:\n",
      "   Total Records: 1,355\n",
      "   âœ… Normal: 1,355 (100.0%)\n",
      "   âŒ Abnormal: 0 (0.0%)\n",
      "   ğŸ‘¥ Gender Distribution:\n",
      "      Female: 691 (51.0%)\n",
      "      Male: 664 (49.0%)\n",
      "   ğŸ¥ Lab Distribution:\n",
      "      Hawkari: 821 (60.6%)\n",
      "      Biolab: 534 (39.4%)\n",
      "\n",
      "ğŸ” COMBINED OUTCOME PATTERNS:\n",
      "   Outcome Pattern Analysis (1003 patients):\n",
      "   ğŸ“Š Blood: abnormal + Serum Creatinine: normal + Blood Glucose: normal\n",
      "      497 patients (49.6%)\n",
      "   ğŸ“Š Blood: abnormal + Serum Creatinine: abnormal + Blood Glucose: normal\n",
      "      185 patients (18.4%)\n",
      "   ğŸ“Š Blood: normal + Serum Creatinine: normal + Blood Glucose: normal\n",
      "      175 patients (17.4%)\n",
      "   ğŸ“Š Blood: normal + Serum Creatinine: abnormal + Blood Glucose: normal\n",
      "      146 patients (14.6%)\n",
      "\n",
      "   ğŸš¨ RISK ANALYSIS:\n",
      "   All Three Tests Normal: 175 (17.4%)\n",
      "   Two or More Tests Abnormal: 185 (18.4%)\n",
      "   All Three Tests Abnormal: 0 (0.0%)\n",
      "\n",
      "====================================================================================================\n",
      "\n",
      "ğŸ¯ SUMMARY TABLE - THREE-TEST COMBINATION OUTCOMES\n",
      "========================================================================================================================\n",
      "                          Test 1                           Test 2                         Test 3  Total Patients Test 1 Abnormal % Test 2 Abnormal % Test 3 Abnormal %\n",
      "     Hepatitis B Surface Antigen             Hepatitis C Antibody                   HIV Antibody            4843              0.2%              0.0%              0.0%\n",
      "                             TSH                 Serum Creatinine                  Blood Glucose            2898             28.3%             36.8%              0.0%\n",
      "                Serum Creatinine            Total Serum Bilirubin                  Blood Glucose            2880             36.7%              0.0%              0.0%\n",
      "                             TSH                 Serum Creatinine          Total Serum Bilirubin            2171             27.2%             37.6%              0.0%\n",
      "                             TSH            Total Serum Bilirubin                  Blood Glucose            2036             27.0%              0.0%              0.0%\n",
      "               Serum Cholesterol              Serum Triglycerides          Serum LDL Cholesterol            1884              0.0%             57.5%             68.6%\n",
      "                Serum Creatinine                    Blood Glucose       C-Reactive Protein Titer            1703             35.8%              0.0%              0.0%\n",
      "               Serum Cholesterol            Serum HDL Cholesterol          Serum LDL Cholesterol            1579              0.0%             37.9%             68.8%\n",
      "             Serum Triglycerides            Serum HDL Cholesterol          Serum LDL Cholesterol            1573             57.1%             38.0%             68.6%\n",
      "               Serum Cholesterol              Serum Triglycerides          Serum HDL Cholesterol            1572              0.0%             57.2%             38.1%\n",
      "                Serum Creatinine Aspartate Aminotransferase (AST) Alanine Aminotransferase (ALT)            1354             28.9%             10.9%              9.5%\n",
      "                           HbA1c                 Serum Creatinine                  Blood Glucose            1208             84.8%             35.7%              0.0%\n",
      "               Total Cholesterol                    Triglycerides                LDL Cholesterol            1120             23.1%             58.6%              0.0%\n",
      "Aspartate Aminotransferase (AST)   Alanine Aminotransferase (ALT)           Alkaline Phosphatase            1111             13.8%             12.4%             15.5%\n",
      "                Serum Creatinine                   Serum Ferritin                  Blood Glucose            1101             44.8%             22.3%              0.0%\n",
      "                Serum Creatinine                    Blood Glucose                LDL Cholesterol            1088             28.1%              0.0%              0.0%\n",
      "                Serum Creatinine            Total Serum Bilirubin       C-Reactive Protein Titer            1072             37.1%              0.0%              0.0%\n",
      "Aspartate Aminotransferase (AST)   Alanine Aminotransferase (ALT)          Total Serum Bilirubin            1060             14.3%             12.1%              0.0%\n",
      "                             TSH                Total Cholesterol                LDL Cholesterol            1048             25.6%             23.0%              0.0%\n",
      "                   Blood Glucose                Total Cholesterol                LDL Cholesterol            1041              0.0%             21.9%              0.0%\n",
      "                             TSH                 Serum Creatinine                 Serum Ferritin            1039             32.4%             43.9%             22.2%\n",
      "     Hepatitis B Surface Antigen             Hepatitis C Antibody                  Blood Glucose            1035              0.1%              0.0%              0.0%\n",
      "     Hepatitis B Surface Antigen                     HIV Antibody                  Blood Glucose            1034              0.1%              0.0%              0.0%\n",
      "            Hepatitis C Antibody                     HIV Antibody                  Blood Glucose            1034              0.0%              0.0%              0.0%\n",
      "           Total Serum Bilirubin                    Blood Glucose       C-Reactive Protein Titer            1031              0.0%              0.0%              0.0%\n",
      "                             TSH                   Serum Ferritin                  Blood Glucose            1027             29.3%             21.7%              0.0%\n",
      "                Serum Creatinine                Total Cholesterol                LDL Cholesterol            1024             28.0%             23.0%              0.0%\n",
      "                             TSH                 Serum Creatinine       C-Reactive Protein Titer            1013             29.8%             37.1%              0.0%\n",
      "                             TSH                 Serum Creatinine                LDL Cholesterol            1004             24.8%             29.4%              0.0%\n",
      "             Blood Urea Nitrogen                 Serum Creatinine                  Blood Glucose            1003             73.0%             34.2%              0.0%\n",
      "\n",
      "âœ… ANALYSIS COMPLETE!\n",
      "ğŸ“ˆ Analyzed 30 test combinations covering 44,586 total patient-test-triplet instances\n"
     ]
    }
   ],
   "source": [
    "# Show the Outcome status for each of the test combinations\n",
    "print(\"=== OUTCOME DISTRIBUTION ANALYSIS FOR TEST COMBINATIONS ===\")\n",
    "print(f\"Analyzing {len(results_df)} test combinations with >1000 patients each\")\n",
    "print(\"\\n\" + \"=\"*100)\n",
    "\n",
    "# For each combination, show detailed outcome breakdown\n",
    "for idx, row in results_df.iterrows():\n",
    "    test1, test2, test3 = row['tests']\n",
    "    patient_count = row['count']\n",
    "    \n",
    "    print(f\"\\nğŸ§ª TEST COMBINATION: {test1} + {test2} + {test3}\")\n",
    "    print(f\"ğŸ“Š Total Patients: {patient_count:,}\")\n",
    "    print(\"-\" * 80)\n",
    "\n",
    "    # Get patients who have all three tests\n",
    "    patients_with_all = df_pivot[(df_pivot[test1] > 0) & (df_pivot[test2] > 0) & (df_pivot[test3] > 0)].index\n",
    "\n",
    "    # Filter the main dataset for these patients and all tests\n",
    "    combo_data = df[\n",
    "        (df['Patient Name'].isin(patients_with_all)) & \n",
    "        (df['Standard Test Name'].isin([test1, test2, test3]))\n",
    "    ].copy()\n",
    "    \n",
    "    # Analyze outcomes for each test separately\n",
    "    for test_name in [test1, test2, test3]:\n",
    "        test_data = combo_data[combo_data['Standard Test Name'] == test_name]\n",
    "        \n",
    "        print(f\"\\nğŸ“‹ {test_name}:\")\n",
    "        print(f\"   Total Records: {len(test_data):,}\")\n",
    "        \n",
    "        # Outcome distribution\n",
    "        outcome_dist = test_data['Outcome'].value_counts()\n",
    "        total_records = len(test_data)\n",
    "        \n",
    "        for outcome in ['normal', 'abnormal']:\n",
    "            count = outcome_dist.get(outcome, 0)\n",
    "            percentage = (count / total_records * 100) if total_records > 0 else 0\n",
    "            outcome_name = {'normal': 'Normal', 'abnormal': 'Abnormal'}[outcome]\n",
    "            emoji = {'normal': 'âœ…', 'abnormal': 'âŒ'}[outcome]\n",
    "            print(f\"   {emoji} {outcome_name}: {count:,} ({percentage:.1f}%)\")\n",
    "        \n",
    "        # Gender breakdown\n",
    "        gender_dist = test_data['Gender'].value_counts()\n",
    "        print(f\"   ğŸ‘¥ Gender Distribution:\")\n",
    "        for gender, count in gender_dist.items():\n",
    "            percentage = (count / total_records * 100) if total_records > 0 else 0\n",
    "            print(f\"      {gender}: {count:,} ({percentage:.1f}%)\")\n",
    "        \n",
    "        # Lab distribution\n",
    "        lab_dist = test_data['Lab'].value_counts()\n",
    "        print(f\"   ğŸ¥ Lab Distribution:\")\n",
    "        for lab, count in lab_dist.items():\n",
    "            percentage = (count / total_records * 100) if total_records > 0 else 0\n",
    "            print(f\"      {lab}: {count:,} ({percentage:.1f}%)\")\n",
    "    \n",
    "    # Combined analysis - look at outcome patterns for patients with all three tests\n",
    "    print(f\"\\nğŸ” COMBINED OUTCOME PATTERNS:\")\n",
    "    \n",
    "    # Create a summary for each patient showing their outcomes for all three tests\n",
    "    patient_outcomes = []\n",
    "    for patient in patients_with_all:\n",
    "        patient_data = combo_data[combo_data['Patient Name'] == patient]\n",
    "        \n",
    "        test1_outcomes = patient_data[patient_data['Standard Test Name'] == test1]['Outcome'].values\n",
    "        test2_outcomes = patient_data[patient_data['Standard Test Name'] == test2]['Outcome'].values\n",
    "        test3_outcomes = patient_data[patient_data['Standard Test Name'] == test3]['Outcome'].values\n",
    "        \n",
    "        if len(test1_outcomes) > 0 and len(test2_outcomes) > 0 and len(test3_outcomes) > 0:\n",
    "            # Take the most recent outcome for each test\n",
    "            test1_outcome = test1_outcomes[-1]  # Most recent\n",
    "            test2_outcome = test2_outcomes[-1]  # Most recent\n",
    "            test3_outcome = test3_outcomes[-1]  # Most recent\n",
    "            \n",
    "            patient_outcomes.append({\n",
    "                'patient': patient,\n",
    "                'test1_outcome': test1_outcome,\n",
    "                'test2_outcome': test2_outcome,\n",
    "                'test3_outcome': test3_outcome,\n",
    "                'combination': f\"{test1_outcome}-{test2_outcome}-{test3_outcome}\"\n",
    "            })\n",
    "    \n",
    "    # Analyze outcome combinations\n",
    "    if patient_outcomes:\n",
    "        combo_df = pd.DataFrame(patient_outcomes)\n",
    "        combo_counts = combo_df['combination'].value_counts()\n",
    "        \n",
    "        print(f\"   Outcome Pattern Analysis ({len(patient_outcomes)} patients):\")\n",
    "        for combo, count in combo_counts.head(10).items():  # Show top 10 combinations\n",
    "            percentage = (count / len(patient_outcomes) * 100)\n",
    "            test1_out, test2_out, test3_out = combo.split('-')\n",
    "            \n",
    "            test1_name_short = test1.split()[0] if len(test1.split()) > 2 else test1\n",
    "            test2_name_short = test2.split()[0] if len(test2.split()) > 2 else test2\n",
    "            test3_name_short = test3.split()[0] if len(test3.split()) > 2 else test3\n",
    "            \n",
    "            print(f\"   ğŸ“Š {test1_name_short}: {test1_out} + {test2_name_short}: {test2_out} + {test3_name_short}: {test3_out}\")\n",
    "            print(f\"      {count:,} patients ({percentage:.1f}%)\")\n",
    "        \n",
    "        # Risk analysis - patients with abnormal results in multiple tests\n",
    "        all_normal = combo_df[\n",
    "            (combo_df['test1_outcome'] == 'normal') & \n",
    "            (combo_df['test2_outcome'] == 'normal') & \n",
    "            (combo_df['test3_outcome'] == 'normal')\n",
    "        ]\n",
    "        \n",
    "        two_abnormal = combo_df[\n",
    "            ((combo_df['test1_outcome'] != 'normal') & (combo_df['test2_outcome'] != 'normal')) |\n",
    "            ((combo_df['test1_outcome'] != 'normal') & (combo_df['test3_outcome'] != 'normal')) |\n",
    "            ((combo_df['test2_outcome'] != 'normal') & (combo_df['test3_outcome'] != 'normal'))\n",
    "        ]\n",
    "        \n",
    "        all_abnormal = combo_df[\n",
    "            (combo_df['test1_outcome'] != 'normal') & \n",
    "            (combo_df['test2_outcome'] != 'normal') & \n",
    "            (combo_df['test3_outcome'] != 'normal')\n",
    "        ]\n",
    "        \n",
    "        print(f\"\\n   ğŸš¨ RISK ANALYSIS:\")\n",
    "        print(f\"   All Three Tests Normal: {len(all_normal):,} ({len(all_normal)/len(patient_outcomes)*100:.1f}%)\")\n",
    "        print(f\"   Two or More Tests Abnormal: {len(two_abnormal):,} ({len(two_abnormal)/len(patient_outcomes)*100:.1f}%)\")\n",
    "        print(f\"   All Three Tests Abnormal: {len(all_abnormal):,} ({len(all_abnormal)/len(patient_outcomes)*100:.1f}%)\")\n",
    "    \n",
    "    print(\"\\n\" + \"=\"*100)\n",
    "\n",
    "# Summary table of all combinations\n",
    "print(f\"\\nğŸ¯ SUMMARY TABLE - THREE-TEST COMBINATION OUTCOMES\")\n",
    "print(\"=\"*120)\n",
    "\n",
    "summary_data = []\n",
    "for idx, row in results_df.iterrows():\n",
    "    test1, test2, test3 = row['tests']\n",
    "    patient_count = row['count']\n",
    "    \n",
    "    # Get patients who have all three tests\n",
    "    patients_with_all = df_pivot[(df_pivot[test1] > 0) & (df_pivot[test2] > 0) & (df_pivot[test3] > 0)].index\n",
    "    combo_data = df[\n",
    "        (df['Patient Name'].isin(patients_with_all)) & \n",
    "        (df['Standard Test Name'].isin([test1, test2, test3]))\n",
    "    ].copy()\n",
    "    \n",
    "    # Calculate summary stats\n",
    "    test1_data = combo_data[combo_data['Standard Test Name'] == test1]\n",
    "    test2_data = combo_data[combo_data['Standard Test Name'] == test2]\n",
    "    test3_data = combo_data[combo_data['Standard Test Name'] == test3]\n",
    "    \n",
    "    test1_abnormal = len(test1_data[test1_data['Outcome'] != 'normal'])\n",
    "    test2_abnormal = len(test2_data[test2_data['Outcome'] != 'normal'])\n",
    "    test3_abnormal = len(test3_data[test3_data['Outcome'] != 'normal'])\n",
    "    \n",
    "    test1_abnormal_pct = (test1_abnormal / len(test1_data) * 100) if len(test1_data) > 0 else 0\n",
    "    test2_abnormal_pct = (test2_abnormal / len(test2_data) * 100) if len(test2_data) > 0 else 0\n",
    "    test3_abnormal_pct = (test3_abnormal / len(test3_data) * 100) if len(test3_data) > 0 else 0\n",
    "    \n",
    "    summary_data.append({\n",
    "        'Test 1': test1,\n",
    "        'Test 2': test2,\n",
    "        'Test 3': test3,\n",
    "        'Total Patients': patient_count,\n",
    "        'Test 1 Abnormal %': f\"{test1_abnormal_pct:.1f}%\",\n",
    "        'Test 2 Abnormal %': f\"{test2_abnormal_pct:.1f}%\",\n",
    "        'Test 3 Abnormal %': f\"{test3_abnormal_pct:.1f}%\"\n",
    "    })\n",
    "\n",
    "summary_df = pd.DataFrame(summary_data)\n",
    "print(summary_df.to_string(index=False))\n",
    "\n",
    "print(f\"\\nâœ… ANALYSIS COMPLETE!\")\n",
    "print(f\"ğŸ“ˆ Analyzed {len(results_df)} test combinations covering {results_df['count'].sum():,} total patient-test-triplet instances\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "1d168816",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "ğŸ¯ ENHANCED SUMMARY TABLE - THREE-TEST COMBINATION OUTCOMES WITH RISK ANALYSIS\n",
      "================================================================================================================================================================\n",
      "                          Test 1                           Test 2                         Test 3  Total Patients Test 1 Abnormal % Test 2 Abnormal % Test 3 Abnormal % All 3 Abnormal % All 3 Normal % 2+ Abnormal % 1 Abnormal %\n",
      "     Hepatitis B Surface Antigen             Hepatitis C Antibody                   HIV Antibody            4843              0.2%              0.0%              0.0%             0.0%          99.8%          0.0%         0.2%\n",
      "                             TSH                 Serum Creatinine                  Blood Glucose            2898             28.3%             36.8%              0.0%             0.0%          48.9%          8.5%        42.6%\n",
      "                Serum Creatinine            Total Serum Bilirubin                  Blood Glucose            2880             36.7%              0.0%              0.0%             0.0%          64.0%          0.0%        36.0%\n",
      "                             TSH                 Serum Creatinine          Total Serum Bilirubin            2171             27.2%             37.6%              0.0%             0.0%          48.5%          7.9%        43.6%\n",
      "                             TSH            Total Serum Bilirubin                  Blood Glucose            2036             27.0%              0.0%              0.0%             0.0%          78.0%          0.0%        22.0%\n",
      "               Serum Cholesterol              Serum Triglycerides          Serum LDL Cholesterol            1884              0.0%             57.5%             68.6%             0.0%          19.6%         40.1%        40.3%\n",
      "                Serum Creatinine                    Blood Glucose       C-Reactive Protein Titer            1703             35.8%              0.0%              0.0%             0.0%          65.6%          0.0%        34.4%\n",
      "               Serum Cholesterol            Serum HDL Cholesterol          Serum LDL Cholesterol            1579              0.0%             37.9%             68.8%             0.0%          19.1%         23.7%        57.2%\n",
      "             Serum Triglycerides            Serum HDL Cholesterol          Serum LDL Cholesterol            1573             57.1%             38.0%             68.6%            18.6%          14.7%         52.6%        32.6%\n",
      "               Serum Cholesterol              Serum Triglycerides          Serum HDL Cholesterol            1572              0.0%             57.2%             38.1%             0.1%          37.3%         26.1%        36.6%\n",
      "                Serum Creatinine Aspartate Aminotransferase (AST) Alanine Aminotransferase (ALT)            1354             28.9%             10.9%              9.5%             1.7%          62.7%          7.1%        30.2%\n",
      "                           HbA1c                 Serum Creatinine                  Blood Glucose            1208             84.8%             35.7%              0.0%             0.0%          11.8%         29.3%        58.9%\n",
      "               Total Cholesterol                    Triglycerides                LDL Cholesterol            1120             23.1%             58.6%              0.0%             0.0%          34.6%         15.5%        49.9%\n",
      "Aspartate Aminotransferase (AST)   Alanine Aminotransferase (ALT)           Alkaline Phosphatase            1111             13.8%             12.4%             15.5%             2.3%          75.0%          8.9%        16.1%\n",
      "                Serum Creatinine                   Serum Ferritin                  Blood Glucose            1101             44.8%             22.3%              0.0%             0.0%          44.9%          9.6%        45.5%\n",
      "                Serum Creatinine                    Blood Glucose                LDL Cholesterol            1088             28.1%              0.0%              0.0%             0.0%          72.2%          0.0%        27.8%\n",
      "                Serum Creatinine            Total Serum Bilirubin       C-Reactive Protein Titer            1072             37.1%              0.0%              0.0%             0.0%          65.3%          0.0%        34.7%\n",
      "Aspartate Aminotransferase (AST)   Alanine Aminotransferase (ALT)          Total Serum Bilirubin            1060             14.3%             12.1%              0.0%             0.0%          84.2%          6.6%         9.2%\n",
      "                             TSH                Total Cholesterol                LDL Cholesterol            1048             25.6%             23.0%              0.0%             0.0%          61.7%          5.1%        33.2%\n",
      "                   Blood Glucose                Total Cholesterol                LDL Cholesterol            1041              0.0%             21.9%              0.0%             0.0%          78.9%          0.0%        21.1%\n",
      "                             TSH                 Serum Creatinine                 Serum Ferritin            1039             32.4%             43.9%             22.2%             1.9%          34.0%         20.2%        45.8%\n",
      "     Hepatitis B Surface Antigen             Hepatitis C Antibody                  Blood Glucose            1035              0.1%              0.0%              0.0%             0.0%          99.9%          0.0%         0.1%\n",
      "     Hepatitis B Surface Antigen                     HIV Antibody                  Blood Glucose            1034              0.1%              0.0%              0.0%             0.0%          99.9%          0.0%         0.1%\n",
      "            Hepatitis C Antibody                     HIV Antibody                  Blood Glucose            1034              0.0%              0.0%              0.0%             0.0%         100.0%          0.0%         0.0%\n",
      "           Total Serum Bilirubin                    Blood Glucose       C-Reactive Protein Titer            1031              0.0%              0.0%              0.0%             0.0%         100.0%          0.0%         0.0%\n",
      "                             TSH                   Serum Ferritin                  Blood Glucose            1027             29.3%             21.7%              0.0%             0.0%          62.3%          3.8%        33.9%\n",
      "                Serum Creatinine                Total Cholesterol                LDL Cholesterol            1024             28.0%             23.0%              0.0%             0.0%          56.4%          6.7%        36.8%\n",
      "                             TSH                 Serum Creatinine       C-Reactive Protein Titer            1013             29.8%             37.1%              0.0%             0.0%          49.7%          9.7%        40.7%\n",
      "                             TSH                 Serum Creatinine                LDL Cholesterol            1004             24.8%             29.4%              0.0%             0.0%          55.7%          5.6%        38.7%\n",
      "             Blood Urea Nitrogen                 Serum Creatinine                  Blood Glucose            1003             73.0%             34.2%              0.0%             0.0%          17.4%         18.4%        64.1%\n",
      "\n",
      "ğŸ“Š KEY INSIGHTS FROM ENHANCED THREE-TEST ANALYSIS:\n",
      "======================================================================\n",
      "\n",
      "ğŸš¨ HIGHEST RISK COMBINATIONS (All 3 Tests Abnormal):\n",
      "1. Serum Triglycerides + Serum HDL Cholesterol + Serum LDL Cholesterol: 18.6% (1573 patients)\n",
      "2. Aspartate Aminotransferase (AST) + Alanine Aminotransferase (ALT) + Alkaline Phosphatase: 2.3% (1111 patients)\n",
      "3. TSH + Serum Creatinine + Serum Ferritin: 1.9% (1039 patients)\n",
      "\n",
      "âœ… LOWEST RISK COMBINATIONS (All 3 Tests Normal):\n",
      "1. Hepatitis C Antibody + HIV Antibody + Blood Glucose: 100.0% (1034 patients)\n",
      "2. Total Serum Bilirubin + Blood Glucose + C-Reactive Protein Titer: 100.0% (1031 patients)\n",
      "3. Hepatitis B Surface Antigen + Hepatitis C Antibody + Blood Glucose: 99.9% (1035 patients)\n",
      "\n",
      "âš ï¸ HIGHEST MULTI-TEST RISK (2+ Tests Abnormal):\n",
      "1. Serum Triglycerides + Serum HDL Cholesterol + Serum LDL Cholesterol: 52.6% (1573 patients)\n",
      "2. Serum Cholesterol + Serum Triglycerides + Serum LDL Cholesterol: 40.1% (1884 patients)\n",
      "3. HbA1c + Serum Creatinine + Blood Glucose: 29.3% (1208 patients)\n",
      "\n",
      "ğŸ” MOST ISOLATED ABNORMALITIES (Only 1 Test Abnormal):\n",
      "1. Blood Urea Nitrogen + Serum Creatinine + Blood Glucose: 64.1% (1003 patients)\n",
      "2. HbA1c + Serum Creatinine + Blood Glucose: 58.9% (1208 patients)\n",
      "3. Serum Cholesterol + Serum HDL Cholesterol + Serum LDL Cholesterol: 57.2% (1579 patients)\n",
      "\n",
      "âœ… ENHANCED THREE-TEST ANALYSIS COMPLETE!\n",
      "ğŸ“ˆ Enhanced summary includes individual and combined risk analysis for all 30 three-test combinations\n"
     ]
    }
   ],
   "source": [
    "# Enhanced Summary table including combined outcome analysis for 3 tests\n",
    "print(f\"\\nğŸ¯ ENHANCED SUMMARY TABLE - THREE-TEST COMBINATION OUTCOMES WITH RISK ANALYSIS\")\n",
    "print(\"=\"*160)\n",
    "\n",
    "enhanced_summary_data = []\n",
    "for idx, row in results_df.iterrows():\n",
    "    test1, test2, test3 = row['tests']\n",
    "    patient_count = row['count']\n",
    "    \n",
    "    # Get patients who have all three tests\n",
    "    patients_with_all = df_pivot[(df_pivot[test1] > 0) & (df_pivot[test2] > 0) & (df_pivot[test3] > 0)].index\n",
    "    combo_data = df[\n",
    "        (df['Patient Name'].isin(patients_with_all)) & \n",
    "        (df['Standard Test Name'].isin([test1, test2, test3]))\n",
    "    ].copy()\n",
    "    \n",
    "    # Calculate summary stats for individual tests\n",
    "    test1_data = combo_data[combo_data['Standard Test Name'] == test1]\n",
    "    test2_data = combo_data[combo_data['Standard Test Name'] == test2]\n",
    "    test3_data = combo_data[combo_data['Standard Test Name'] == test3]\n",
    "    \n",
    "    test1_abnormal = len(test1_data[test1_data['Outcome'] != 'normal'])\n",
    "    test2_abnormal = len(test2_data[test2_data['Outcome'] != 'normal'])\n",
    "    test3_abnormal = len(test3_data[test3_data['Outcome'] != 'normal'])\n",
    "    \n",
    "    test1_abnormal_pct = (test1_abnormal / len(test1_data) * 100) if len(test1_data) > 0 else 0\n",
    "    test2_abnormal_pct = (test2_abnormal / len(test2_data) * 100) if len(test2_data) > 0 else 0\n",
    "    test3_abnormal_pct = (test3_abnormal / len(test3_data) * 100) if len(test3_data) > 0 else 0\n",
    "    \n",
    "    # Calculate combined outcome patterns\n",
    "    patient_outcomes = []\n",
    "    for patient in patients_with_all:\n",
    "        patient_data = combo_data[combo_data['Patient Name'] == patient]\n",
    "        \n",
    "        test1_outcomes = patient_data[patient_data['Standard Test Name'] == test1]['Outcome'].values\n",
    "        test2_outcomes = patient_data[patient_data['Standard Test Name'] == test2]['Outcome'].values\n",
    "        test3_outcomes = patient_data[patient_data['Standard Test Name'] == test3]['Outcome'].values\n",
    "        \n",
    "        if len(test1_outcomes) > 0 and len(test2_outcomes) > 0 and len(test3_outcomes) > 0:\n",
    "            # Take the most recent outcome for each test\n",
    "            test1_outcome = test1_outcomes[-1]  # Most recent\n",
    "            test2_outcome = test2_outcomes[-1]  # Most recent\n",
    "            test3_outcome = test3_outcomes[-1]  # Most recent\n",
    "            \n",
    "            patient_outcomes.append({\n",
    "                'patient': patient,\n",
    "                'test1_outcome': test1_outcome,\n",
    "                'test2_outcome': test2_outcome,\n",
    "                'test3_outcome': test3_outcome\n",
    "            })\n",
    "    \n",
    "    # Analyze combined risk patterns\n",
    "    if patient_outcomes:\n",
    "        combo_df = pd.DataFrame(patient_outcomes)\n",
    "        \n",
    "        all_abnormal = combo_df[\n",
    "            (combo_df['test1_outcome'] != 'normal') & \n",
    "            (combo_df['test2_outcome'] != 'normal') & \n",
    "            (combo_df['test3_outcome'] != 'normal')\n",
    "        ]\n",
    "        \n",
    "        all_normal = combo_df[\n",
    "            (combo_df['test1_outcome'] == 'normal') & \n",
    "            (combo_df['test2_outcome'] == 'normal') & \n",
    "            (combo_df['test3_outcome'] == 'normal')\n",
    "        ]\n",
    "        \n",
    "        two_abnormal = combo_df[\n",
    "            ((combo_df['test1_outcome'] != 'normal') & (combo_df['test2_outcome'] != 'normal')) |\n",
    "            ((combo_df['test1_outcome'] != 'normal') & (combo_df['test3_outcome'] != 'normal')) |\n",
    "            ((combo_df['test2_outcome'] != 'normal') & (combo_df['test3_outcome'] != 'normal'))\n",
    "        ]\n",
    "        \n",
    "        one_abnormal = combo_df[\n",
    "            ((combo_df['test1_outcome'] != 'normal') & (combo_df['test2_outcome'] == 'normal') & (combo_df['test3_outcome'] == 'normal')) |\n",
    "            ((combo_df['test1_outcome'] == 'normal') & (combo_df['test2_outcome'] != 'normal') & (combo_df['test3_outcome'] == 'normal')) |\n",
    "            ((combo_df['test1_outcome'] == 'normal') & (combo_df['test2_outcome'] == 'normal') & (combo_df['test3_outcome'] != 'normal'))\n",
    "        ]\n",
    "        \n",
    "        all_abnormal_pct = len(all_abnormal) / len(combo_df) * 100\n",
    "        all_normal_pct = len(all_normal) / len(combo_df) * 100\n",
    "        two_abnormal_pct = len(two_abnormal) / len(combo_df) * 100\n",
    "        one_abnormal_pct = len(one_abnormal) / len(combo_df) * 100\n",
    "    else:\n",
    "        all_abnormal_pct = 0\n",
    "        all_normal_pct = 0\n",
    "        two_abnormal_pct = 0\n",
    "        one_abnormal_pct = 0\n",
    "    \n",
    "    enhanced_summary_data.append({\n",
    "        'Test 1': test1,\n",
    "        'Test 2': test2,\n",
    "        'Test 3': test3,\n",
    "        'Total Patients': patient_count,\n",
    "        'Test 1 Abnormal %': f\"{test1_abnormal_pct:.1f}%\",\n",
    "        'Test 2 Abnormal %': f\"{test2_abnormal_pct:.1f}%\",\n",
    "        'Test 3 Abnormal %': f\"{test3_abnormal_pct:.1f}%\",\n",
    "        'All 3 Abnormal %': f\"{all_abnormal_pct:.1f}%\",\n",
    "        'All 3 Normal %': f\"{all_normal_pct:.1f}%\",\n",
    "        '2+ Abnormal %': f\"{two_abnormal_pct:.1f}%\",\n",
    "        '1 Abnormal %': f\"{one_abnormal_pct:.1f}%\"\n",
    "    })\n",
    "\n",
    "enhanced_summary_df = pd.DataFrame(enhanced_summary_data)\n",
    "\n",
    "# Display the enhanced summary table\n",
    "print(enhanced_summary_df.to_string(index=False))\n",
    "\n",
    "# Show some key insights\n",
    "print(f\"\\nğŸ“Š KEY INSIGHTS FROM ENHANCED THREE-TEST ANALYSIS:\")\n",
    "print(\"=\"*70)\n",
    "\n",
    "# Find test combinations with highest risk (all three abnormal)\n",
    "enhanced_summary_df['All_Abnormal_Numeric'] = enhanced_summary_df['All 3 Abnormal %'].str.rstrip('%').astype(float)\n",
    "highest_risk = enhanced_summary_df.nlargest(3, 'All_Abnormal_Numeric')\n",
    "\n",
    "print(f\"\\nğŸš¨ HIGHEST RISK COMBINATIONS (All 3 Tests Abnormal):\")\n",
    "for i, (_, row) in enumerate(highest_risk.iterrows(), 1):\n",
    "    print(f\"{i}. {row['Test 1']} + {row['Test 2']} + {row['Test 3']}: {row['All 3 Abnormal %']} ({row['Total Patients']} patients)\")\n",
    "\n",
    "# Find test combinations with highest normal rates\n",
    "enhanced_summary_df['All_Normal_Numeric'] = enhanced_summary_df['All 3 Normal %'].str.rstrip('%').astype(float)\n",
    "lowest_risk = enhanced_summary_df.nlargest(3, 'All_Normal_Numeric')\n",
    "\n",
    "print(f\"\\nâœ… LOWEST RISK COMBINATIONS (All 3 Tests Normal):\")\n",
    "for i, (_, row) in enumerate(lowest_risk.iterrows(), 1):\n",
    "    print(f\"{i}. {row['Test 1']} + {row['Test 2']} + {row['Test 3']}: {row['All 3 Normal %']} ({row['Total Patients']} patients)\")\n",
    "\n",
    "# Find test combinations with most patients having 2 or more abnormal tests\n",
    "enhanced_summary_df['Two_Plus_Abnormal_Numeric'] = enhanced_summary_df['2+ Abnormal %'].str.rstrip('%').astype(float)\n",
    "highest_multi_risk = enhanced_summary_df.nlargest(3, 'Two_Plus_Abnormal_Numeric')\n",
    "\n",
    "print(f\"\\nâš ï¸ HIGHEST MULTI-TEST RISK (2+ Tests Abnormal):\")\n",
    "for i, (_, row) in enumerate(highest_multi_risk.iterrows(), 1):\n",
    "    print(f\"{i}. {row['Test 1']} + {row['Test 2']} + {row['Test 3']}: {row['2+ Abnormal %']} ({row['Total Patients']} patients)\")\n",
    "\n",
    "# Find test combinations with most single abnormal results\n",
    "enhanced_summary_df['One_Abnormal_Numeric'] = enhanced_summary_df['1 Abnormal %'].str.rstrip('%').astype(float)\n",
    "most_single_abnormal = enhanced_summary_df.nlargest(3, 'One_Abnormal_Numeric')\n",
    "\n",
    "print(f\"\\nğŸ” MOST ISOLATED ABNORMALITIES (Only 1 Test Abnormal):\")\n",
    "for i, (_, row) in enumerate(most_single_abnormal.iterrows(), 1):\n",
    "    print(f\"{i}. {row['Test 1']} + {row['Test 2']} + {row['Test 3']}: {row['1 Abnormal %']} ({row['Total Patients']} patients)\")\n",
    "\n",
    "print(f\"\\nâœ… ENHANCED THREE-TEST ANALYSIS COMPLETE!\")\n",
    "print(f\"ğŸ“ˆ Enhanced summary includes individual and combined risk analysis for all {len(enhanced_summary_df)} three-test combinations\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "64196a71",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1600x1000 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ğŸ† TOP 5 HIGHEST RISK THREE-TEST COMBINATIONS\n",
      "======================================================================\n",
      "1. Serum Triglycerides + Serum HDL Cholesterol + Serum LDL Cholesterol\n",
      "   ğŸš¨ All 3 Tests Abnormal: 18.6%\n",
      "   ğŸ‘¥ Total Patients: 1,573\n",
      "   ğŸ“ˆ Individual Abnormal Rates: 57.1% | 38.0% | 68.6%\n",
      "   âš ï¸  2+ Tests Abnormal: 52.6%\n",
      "   âœ… All 3 Tests Normal: 14.7%\n",
      "\n",
      "2. Aspartate Aminotransferase (AST) + Alanine Aminotransferase (ALT) + Alkaline Phosphatase\n",
      "   ğŸš¨ All 3 Tests Abnormal: 2.3%\n",
      "   ğŸ‘¥ Total Patients: 1,111\n",
      "   ğŸ“ˆ Individual Abnormal Rates: 13.8% | 12.4% | 15.5%\n",
      "   âš ï¸  2+ Tests Abnormal: 8.9%\n",
      "   âœ… All 3 Tests Normal: 75.0%\n",
      "\n",
      "3. TSH + Serum Creatinine + Serum Ferritin\n",
      "   ğŸš¨ All 3 Tests Abnormal: 1.9%\n",
      "   ğŸ‘¥ Total Patients: 1,039\n",
      "   ğŸ“ˆ Individual Abnormal Rates: 32.4% | 43.9% | 22.2%\n",
      "   âš ï¸  2+ Tests Abnormal: 20.2%\n",
      "   âœ… All 3 Tests Normal: 34.0%\n",
      "\n",
      "4. Serum Creatinine + Aspartate Aminotransferase (AST) + Alanine Aminotransferase (ALT)\n",
      "   ğŸš¨ All 3 Tests Abnormal: 1.7%\n",
      "   ğŸ‘¥ Total Patients: 1,354\n",
      "   ğŸ“ˆ Individual Abnormal Rates: 28.9% | 10.9% | 9.5%\n",
      "   âš ï¸  2+ Tests Abnormal: 7.1%\n",
      "   âœ… All 3 Tests Normal: 62.7%\n",
      "\n",
      "5. Serum Cholesterol + Serum Triglycerides + Serum HDL Cholesterol\n",
      "   ğŸš¨ All 3 Tests Abnormal: 0.1%\n",
      "   ğŸ‘¥ Total Patients: 1,572\n",
      "   ğŸ“ˆ Individual Abnormal Rates: 0.0% | 57.2% | 38.1%\n",
      "   âš ï¸  2+ Tests Abnormal: 26.1%\n",
      "   âœ… All 3 Tests Normal: 37.3%\n",
      "\n",
      "ğŸ’¡ INSIGHTS:\n",
      "- Higher percentages indicate test combinations where patients frequently show abnormal results in all three tests\n",
      "- These combinations may indicate complex health conditions or multiple related risk factors\n",
      "- The patient count shows the statistical significance of each combination\n",
      "- 2+ Abnormal percentage shows broader risk patterns beyond just all three abnormal\n"
     ]
    }
   ],
   "source": [
    "# Create a bar chart for the top 5 test combinations with highest \"All 3 Tests Abnormal\" percentages\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "# Get the top 5 combinations with highest all 3 abnormal percentages\n",
    "top_5_highest_risk = enhanced_summary_df.nlargest(5, 'All_Abnormal_Numeric')\n",
    "\n",
    "# Create the figure and axis\n",
    "plt.figure(figsize=(16, 10))\n",
    "\n",
    "# Prepare data for plotting\n",
    "test_combinations = []\n",
    "all_abnormal_values = []\n",
    "\n",
    "for _, row in top_5_highest_risk.iterrows():\n",
    "    # Create shorter labels for better readability\n",
    "    test1_short = row['Test 1'].split()[0] if len(row['Test 1'].split()) > 2 else row['Test 1']\n",
    "    test2_short = row['Test 2'].split()[0] if len(row['Test 2'].split()) > 2 else row['Test 2']\n",
    "    test3_short = row['Test 3'].split()[0] if len(row['Test 3'].split()) > 2 else row['Test 3']\n",
    "    \n",
    "    combination_label = f\"{test1_short}\\n+\\n{test2_short}\\n+\\n{test3_short}\\n({row['Total Patients']} patients)\"\n",
    "    test_combinations.append(combination_label)\n",
    "    all_abnormal_values.append(row['All_Abnormal_Numeric'])\n",
    "\n",
    "# Create the bar chart\n",
    "bars = plt.bar(range(len(test_combinations)), all_abnormal_values, \n",
    "               color=['#FF6B6B', '#4ECDC4', '#45B7D1', '#FFA07A', '#98D8C8'],\n",
    "               edgecolor='black', linewidth=1.5, alpha=0.8)\n",
    "\n",
    "# Customize the chart\n",
    "plt.title('Top 5 Test Combinations with Highest \"All 3 Tests Abnormal\" Percentages', \n",
    "          fontsize=16, fontweight='bold', pad=20)\n",
    "plt.xlabel('Test Combinations', fontsize=12, fontweight='bold')\n",
    "plt.ylabel('All 3 Tests Abnormal (%)', fontsize=12, fontweight='bold')\n",
    "\n",
    "# Set x-axis labels\n",
    "plt.xticks(range(len(test_combinations)), test_combinations, fontsize=10)\n",
    "\n",
    "# Add value labels on top of bars\n",
    "for i, (bar, value) in enumerate(zip(bars, all_abnormal_values)):\n",
    "    plt.text(bar.get_x() + bar.get_width()/2, bar.get_height() + 0.1, \n",
    "             f'{value:.1f}%', ha='center', va='bottom', fontweight='bold', fontsize=11)\n",
    "\n",
    "# Customize grid and layout\n",
    "plt.grid(axis='y', alpha=0.3, linestyle='--')\n",
    "plt.ylim(0, max(all_abnormal_values) * 1.15)\n",
    "\n",
    "# Add a subtle background color\n",
    "plt.gca().set_facecolor('#F8F9FA')\n",
    "\n",
    "# Adjust layout to prevent label cutoff\n",
    "plt.tight_layout()\n",
    "\n",
    "# Show the plot\n",
    "plt.show()\n",
    "\n",
    "# Print summary information\n",
    "print(\"ğŸ† TOP 5 HIGHEST RISK THREE-TEST COMBINATIONS\")\n",
    "print(\"=\"*70)\n",
    "for i, (_, row) in enumerate(top_5_highest_risk.iterrows(), 1):\n",
    "    print(f\"{i}. {row['Test 1']} + {row['Test 2']} + {row['Test 3']}\")\n",
    "    print(f\"   ğŸš¨ All 3 Tests Abnormal: {row['All 3 Abnormal %']}\")\n",
    "    print(f\"   ğŸ‘¥ Total Patients: {row['Total Patients']:,}\")\n",
    "    print(f\"   ğŸ“ˆ Individual Abnormal Rates: {row['Test 1 Abnormal %']} | {row['Test 2 Abnormal %']} | {row['Test 3 Abnormal %']}\")\n",
    "    print(f\"   âš ï¸  2+ Tests Abnormal: {row['2+ Abnormal %']}\")\n",
    "    print(f\"   âœ… All 3 Tests Normal: {row['All 3 Normal %']}\")\n",
    "    print()\n",
    "\n",
    "print(\"ğŸ’¡ INSIGHTS:\")\n",
    "print(\"- Higher percentages indicate test combinations where patients frequently show abnormal results in all three tests\")\n",
    "print(\"- These combinations may indicate complex health conditions or multiple related risk factors\")\n",
    "print(\"- The patient count shows the statistical significance of each combination\")\n",
    "print(\"- 2+ Abnormal percentage shows broader risk patterns beyond just all three abnormal\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "be61efa2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 2000x1000 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ğŸ¯ TOP 5 TEST COMBINATIONS WITH HIGHEST '2+ TESTS ABNORMAL' PERCENTAGES\n",
      "=====================================================================================\n",
      "1. Serum Triglycerides + Serum HDL Cholesterol + Serum LDL Cholesterol\n",
      "   âš ï¸  2+ Tests Abnormal: 52.6%\n",
      "   ğŸš¨ All 3 Tests Abnormal: 18.6%\n",
      "   ğŸ‘¥ Total Patients: 1,573\n",
      "   ğŸ“Š Individual Abnormal Rates: 57.1% | 38.0% | 68.6%\n",
      "   ğŸ“ˆ Average Individual Abnormal Rate: 54.6%\n",
      "   ğŸ”„ Single Test Abnormal: 32.6%\n",
      "   âœ… All 3 Tests Normal: 14.7%\n",
      "\n",
      "2. Serum Cholesterol + Serum Triglycerides + Serum LDL Cholesterol\n",
      "   âš ï¸  2+ Tests Abnormal: 40.1%\n",
      "   ğŸš¨ All 3 Tests Abnormal: 0.0%\n",
      "   ğŸ‘¥ Total Patients: 1,884\n",
      "   ğŸ“Š Individual Abnormal Rates: 0.0% | 57.5% | 68.6%\n",
      "   ğŸ“ˆ Average Individual Abnormal Rate: 42.0%\n",
      "   ğŸ”„ Single Test Abnormal: 40.3%\n",
      "   âœ… All 3 Tests Normal: 19.6%\n",
      "\n",
      "3. HbA1c + Serum Creatinine + Blood Glucose\n",
      "   âš ï¸  2+ Tests Abnormal: 29.3%\n",
      "   ğŸš¨ All 3 Tests Abnormal: 0.0%\n",
      "   ğŸ‘¥ Total Patients: 1,208\n",
      "   ğŸ“Š Individual Abnormal Rates: 84.8% | 35.7% | 0.0%\n",
      "   ğŸ“ˆ Average Individual Abnormal Rate: 40.2%\n",
      "   ğŸ”„ Single Test Abnormal: 58.9%\n",
      "   âœ… All 3 Tests Normal: 11.8%\n",
      "\n",
      "4. Serum Cholesterol + Serum Triglycerides + Serum HDL Cholesterol\n",
      "   âš ï¸  2+ Tests Abnormal: 26.1%\n",
      "   ğŸš¨ All 3 Tests Abnormal: 0.1%\n",
      "   ğŸ‘¥ Total Patients: 1,572\n",
      "   ğŸ“Š Individual Abnormal Rates: 0.0% | 57.2% | 38.1%\n",
      "   ğŸ“ˆ Average Individual Abnormal Rate: 31.8%\n",
      "   ğŸ”„ Single Test Abnormal: 36.6%\n",
      "   âœ… All 3 Tests Normal: 37.3%\n",
      "\n",
      "5. Serum Cholesterol + Serum HDL Cholesterol + Serum LDL Cholesterol\n",
      "   âš ï¸  2+ Tests Abnormal: 23.7%\n",
      "   ğŸš¨ All 3 Tests Abnormal: 0.0%\n",
      "   ğŸ‘¥ Total Patients: 1,579\n",
      "   ğŸ“Š Individual Abnormal Rates: 0.0% | 37.9% | 68.8%\n",
      "   ğŸ“ˆ Average Individual Abnormal Rate: 35.6%\n",
      "   ğŸ”„ Single Test Abnormal: 57.2%\n",
      "   âœ… All 3 Tests Normal: 19.1%\n",
      "\n",
      "ğŸ’¡ KEY INSIGHTS:\n",
      "- '2+ Tests Abnormal' shows combinations where patients often have multiple abnormal results\n",
      "- Higher percentages indicate stronger correlations between test abnormalities\n",
      "- Average individual abnormal rates show the baseline risk for each test type\n",
      "- These patterns can help identify patient risk profiles and comorbidities\n",
      "\n",
      "ğŸ“Š TOP 5 COMBINATIONS BY AVERAGE INDIVIDUAL ABNORMAL RATES\n",
      "======================================================================\n",
      "1. Serum Triglycerides + Serum HDL Cholesterol + Serum LDL Cholesterol\n",
      "   ğŸ“ˆ Average Individual Abnormal Rate: 54.6%\n",
      "   âš ï¸  2+ Tests Abnormal: 52.6%\n",
      "   ğŸ‘¥ Total Patients: 1,573\n",
      "\n",
      "2. Serum Cholesterol + Serum Triglycerides + Serum LDL Cholesterol\n",
      "   ğŸ“ˆ Average Individual Abnormal Rate: 42.0%\n",
      "   âš ï¸  2+ Tests Abnormal: 40.1%\n",
      "   ğŸ‘¥ Total Patients: 1,884\n",
      "\n",
      "3. HbA1c + Serum Creatinine + Blood Glucose\n",
      "   ğŸ“ˆ Average Individual Abnormal Rate: 40.2%\n",
      "   âš ï¸  2+ Tests Abnormal: 29.3%\n",
      "   ğŸ‘¥ Total Patients: 1,208\n",
      "\n",
      "4. Blood Urea Nitrogen + Serum Creatinine + Blood Glucose\n",
      "   ğŸ“ˆ Average Individual Abnormal Rate: 35.7%\n",
      "   âš ï¸  2+ Tests Abnormal: 18.4%\n",
      "   ğŸ‘¥ Total Patients: 1,003\n",
      "\n",
      "5. Serum Cholesterol + Serum HDL Cholesterol + Serum LDL Cholesterol\n",
      "   ğŸ“ˆ Average Individual Abnormal Rate: 35.6%\n",
      "   âš ï¸  2+ Tests Abnormal: 23.7%\n",
      "   ğŸ‘¥ Total Patients: 1,579\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# Create visualizations for 2+ abnormal test combinations\n",
    "\n",
    "# 1. Top 5 combinations with highest \"2+ Abnormal\" percentages\n",
    "top_5_two_plus_abnormal = enhanced_summary_df.nlargest(5, 'Two_Plus_Abnormal_Numeric')\n",
    "\n",
    "# Create subplot figure with two charts\n",
    "fig, (ax1, ax2) = plt.subplots(1, 2, figsize=(20, 10))\n",
    "\n",
    "# Chart 1: Top 5 with highest 2+ abnormal percentages\n",
    "test_combinations_2plus = []\n",
    "two_plus_abnormal_values = []\n",
    "\n",
    "for _, row in top_5_two_plus_abnormal.iterrows():\n",
    "    # Create shorter labels for better readability\n",
    "    test1_short = row['Test 1'].split()[0] if len(row['Test 1'].split()) > 2 else row['Test 1']\n",
    "    test2_short = row['Test 2'].split()[0] if len(row['Test 2'].split()) > 2 else row['Test 2']\n",
    "    test3_short = row['Test 3'].split()[0] if len(row['Test 3'].split()) > 2 else row['Test 3']\n",
    "    \n",
    "    combination_label = f\"{test1_short}\\n+\\n{test2_short}\\n+\\n{test3_short}\\n({row['Total Patients']} patients)\"\n",
    "    test_combinations_2plus.append(combination_label)\n",
    "    two_plus_abnormal_values.append(row['Two_Plus_Abnormal_Numeric'])\n",
    "\n",
    "# Create the first bar chart\n",
    "bars1 = ax1.bar(range(len(test_combinations_2plus)), two_plus_abnormal_values, \n",
    "                color=['#FF6B6B', '#4ECDC4', '#45B7D1', '#FFA07A', '#98D8C8'],\n",
    "                edgecolor='black', linewidth=1.5, alpha=0.8)\n",
    "\n",
    "# Customize the first chart\n",
    "ax1.set_title('Top 5 Test Combinations with Highest \"2+ Tests Abnormal\" Percentages', \n",
    "              fontsize=14, fontweight='bold', pad=20)\n",
    "ax1.set_xlabel('Test Combinations', fontsize=12, fontweight='bold')\n",
    "ax1.set_ylabel('2+ Tests Abnormal (%)', fontsize=12, fontweight='bold')\n",
    "\n",
    "# Set x-axis labels for first chart\n",
    "ax1.set_xticks(range(len(test_combinations_2plus)))\n",
    "ax1.set_xticklabels(test_combinations_2plus, fontsize=9)\n",
    "\n",
    "# Add value labels on top of bars for first chart\n",
    "for i, (bar, value) in enumerate(zip(bars1, two_plus_abnormal_values)):\n",
    "    ax1.text(bar.get_x() + bar.get_width()/2, bar.get_height() + 0.5, \n",
    "             f'{value:.1f}%', ha='center', va='bottom', fontweight='bold', fontsize=10)\n",
    "\n",
    "# Customize grid and layout for first chart\n",
    "ax1.grid(axis='y', alpha=0.3, linestyle='--')\n",
    "ax1.set_ylim(0, max(two_plus_abnormal_values) * 1.15)\n",
    "ax1.set_facecolor('#F8F9FA')\n",
    "\n",
    "# Chart 2: Average of individual abnormal percentages for top 5 two+ abnormal combinations\n",
    "avg_individual_abnormal = []\n",
    "combination_labels_avg = []\n",
    "\n",
    "for _, row in top_5_two_plus_abnormal.iterrows():\n",
    "    # Calculate average of individual test abnormal percentages\n",
    "    test1_pct = float(row['Test 1 Abnormal %'].rstrip('%'))\n",
    "    test2_pct = float(row['Test 2 Abnormal %'].rstrip('%'))\n",
    "    test3_pct = float(row['Test 3 Abnormal %'].rstrip('%'))\n",
    "    \n",
    "    avg_pct = (test1_pct + test2_pct + test3_pct) / 3\n",
    "    avg_individual_abnormal.append(avg_pct)\n",
    "    \n",
    "    # Create shorter labels\n",
    "    test1_short = row['Test 1'].split()[0] if len(row['Test 1'].split()) > 2 else row['Test 1']\n",
    "    test2_short = row['Test 2'].split()[0] if len(row['Test 2'].split()) > 2 else row['Test 2']\n",
    "    test3_short = row['Test 3'].split()[0] if len(row['Test 3'].split()) > 2 else row['Test 3']\n",
    "    \n",
    "    combination_label = f\"{test1_short}\\n+\\n{test2_short}\\n+\\n{test3_short}\\n({row['Total Patients']} patients)\"\n",
    "    combination_labels_avg.append(combination_label)\n",
    "\n",
    "# Create the second bar chart\n",
    "bars2 = ax2.bar(range(len(combination_labels_avg)), avg_individual_abnormal, \n",
    "                color=['#9B59B6', '#E74C3C', '#F39C12', '#2ECC71', '#3498DB'],\n",
    "                edgecolor='black', linewidth=1.5, alpha=0.8)\n",
    "\n",
    "# Customize the second chart\n",
    "ax2.set_title('Average Individual Test Abnormal % for Top 5 \"2+ Abnormal\" Combinations', \n",
    "              fontsize=14, fontweight='bold', pad=20)\n",
    "ax2.set_xlabel('Test Combinations', fontsize=12, fontweight='bold')\n",
    "ax2.set_ylabel('Average Individual Test Abnormal (%)', fontsize=12, fontweight='bold')\n",
    "\n",
    "# Set x-axis labels for second chart\n",
    "ax2.set_xticks(range(len(combination_labels_avg)))\n",
    "ax2.set_xticklabels(combination_labels_avg, fontsize=9)\n",
    "\n",
    "# Add value labels on top of bars for second chart\n",
    "for i, (bar, value) in enumerate(zip(bars2, avg_individual_abnormal)):\n",
    "    ax2.text(bar.get_x() + bar.get_width()/2, bar.get_height() + 0.5, \n",
    "             f'{value:.1f}%', ha='center', va='bottom', fontweight='bold', fontsize=10)\n",
    "\n",
    "# Customize grid and layout for second chart\n",
    "ax2.grid(axis='y', alpha=0.3, linestyle='--')\n",
    "ax2.set_ylim(0, max(avg_individual_abnormal) * 1.15)\n",
    "ax2.set_facecolor('#F8F9FA')\n",
    "\n",
    "# Adjust layout to prevent overlap\n",
    "plt.tight_layout()\n",
    "plt.show()\n",
    "\n",
    "# Print detailed analysis\n",
    "print(\"ğŸ¯ TOP 5 TEST COMBINATIONS WITH HIGHEST '2+ TESTS ABNORMAL' PERCENTAGES\")\n",
    "print(\"=\"*85)\n",
    "for i, (_, row) in enumerate(top_5_two_plus_abnormal.iterrows(), 1):\n",
    "    test1_pct = float(row['Test 1 Abnormal %'].rstrip('%'))\n",
    "    test2_pct = float(row['Test 2 Abnormal %'].rstrip('%'))\n",
    "    test3_pct = float(row['Test 3 Abnormal %'].rstrip('%'))\n",
    "    avg_individual = (test1_pct + test2_pct + test3_pct) / 3\n",
    "    \n",
    "    print(f\"{i}. {row['Test 1']} + {row['Test 2']} + {row['Test 3']}\")\n",
    "    print(f\"   âš ï¸  2+ Tests Abnormal: {row['2+ Abnormal %']}\")\n",
    "    print(f\"   ğŸš¨ All 3 Tests Abnormal: {row['All 3 Abnormal %']}\")\n",
    "    print(f\"   ğŸ‘¥ Total Patients: {row['Total Patients']:,}\")\n",
    "    print(f\"   ğŸ“Š Individual Abnormal Rates: {row['Test 1 Abnormal %']} | {row['Test 2 Abnormal %']} | {row['Test 3 Abnormal %']}\")\n",
    "    print(f\"   ğŸ“ˆ Average Individual Abnormal Rate: {avg_individual:.1f}%\")\n",
    "    print(f\"   ğŸ”„ Single Test Abnormal: {row['1 Abnormal %']}\")\n",
    "    print(f\"   âœ… All 3 Tests Normal: {row['All 3 Normal %']}\")\n",
    "    print()\n",
    "\n",
    "print(\"ğŸ’¡ KEY INSIGHTS:\")\n",
    "print(\"- '2+ Tests Abnormal' shows combinations where patients often have multiple abnormal results\")\n",
    "print(\"- Higher percentages indicate stronger correlations between test abnormalities\")\n",
    "print(\"- Average individual abnormal rates show the baseline risk for each test type\")\n",
    "print(\"- These patterns can help identify patient risk profiles and comorbidities\")\n",
    "\n",
    "# Additional analysis: Find combinations with highest average individual abnormal rates\n",
    "print(f\"\\nğŸ“Š TOP 5 COMBINATIONS BY AVERAGE INDIVIDUAL ABNORMAL RATES\")\n",
    "print(\"=\"*70)\n",
    "\n",
    "# Create a new dataframe with average calculations for all combinations\n",
    "enhanced_summary_df_with_avg = enhanced_summary_df.copy()\n",
    "enhanced_summary_df_with_avg['Avg_Individual_Abnormal'] = enhanced_summary_df_with_avg.apply(\n",
    "    lambda row: (float(row['Test 1 Abnormal %'].rstrip('%')) + \n",
    "                 float(row['Test 2 Abnormal %'].rstrip('%')) + \n",
    "                 float(row['Test 3 Abnormal %'].rstrip('%'))) / 3, axis=1\n",
    ")\n",
    "\n",
    "top_5_avg_individual = enhanced_summary_df_with_avg.nlargest(5, 'Avg_Individual_Abnormal')\n",
    "\n",
    "for i, (_, row) in enumerate(top_5_avg_individual.iterrows(), 1):\n",
    "    print(f\"{i}. {row['Test 1']} + {row['Test 2']} + {row['Test 3']}\")\n",
    "    print(f\"   ğŸ“ˆ Average Individual Abnormal Rate: {row['Avg_Individual_Abnormal']:.1f}%\")\n",
    "    print(f\"   âš ï¸  2+ Tests Abnormal: {row['2+ Abnormal %']}\")\n",
    "    print(f\"   ğŸ‘¥ Total Patients: {row['Total Patients']:,}\")\n",
    "    print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "27b2d2c6",
   "metadata": {},
   "outputs": [],
   "source": [
    "enhanced_summary_df.to_csv('../model_data_insight/enhanced_three_test_combination_summary.csv', index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "914d44c2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Test 1</th>\n",
       "      <th>Test 2</th>\n",
       "      <th>Test 3</th>\n",
       "      <th>Total Patients</th>\n",
       "      <th>Test 1 Abnormal %</th>\n",
       "      <th>Test 2 Abnormal %</th>\n",
       "      <th>Test 3 Abnormal %</th>\n",
       "      <th>All 3 Abnormal %</th>\n",
       "      <th>All 3 Normal %</th>\n",
       "      <th>2+ Abnormal %</th>\n",
       "      <th>1 Abnormal %</th>\n",
       "      <th>All_Abnormal_Numeric</th>\n",
       "      <th>All_Normal_Numeric</th>\n",
       "      <th>Two_Plus_Abnormal_Numeric</th>\n",
       "      <th>One_Abnormal_Numeric</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Hepatitis B Surface Antigen</td>\n",
       "      <td>Hepatitis C Antibody</td>\n",
       "      <td>HIV Antibody</td>\n",
       "      <td>4843</td>\n",
       "      <td>0.2%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>99.8%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.2%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>99.8</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>TSH</td>\n",
       "      <td>Serum Creatinine</td>\n",
       "      <td>Blood Glucose</td>\n",
       "      <td>2898</td>\n",
       "      <td>28.3%</td>\n",
       "      <td>36.8%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>48.9%</td>\n",
       "      <td>8.5%</td>\n",
       "      <td>42.6%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>48.9</td>\n",
       "      <td>8.5</td>\n",
       "      <td>42.6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Serum Creatinine</td>\n",
       "      <td>Total Serum Bilirubin</td>\n",
       "      <td>Blood Glucose</td>\n",
       "      <td>2880</td>\n",
       "      <td>36.7%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>64.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>36.0%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>64.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>36.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>TSH</td>\n",
       "      <td>Serum Creatinine</td>\n",
       "      <td>Total Serum Bilirubin</td>\n",
       "      <td>2171</td>\n",
       "      <td>27.2%</td>\n",
       "      <td>37.6%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>48.5%</td>\n",
       "      <td>7.9%</td>\n",
       "      <td>43.6%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>48.5</td>\n",
       "      <td>7.9</td>\n",
       "      <td>43.6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>TSH</td>\n",
       "      <td>Total Serum Bilirubin</td>\n",
       "      <td>Blood Glucose</td>\n",
       "      <td>2036</td>\n",
       "      <td>27.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>78.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>22.0%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>78.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>22.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Serum Cholesterol</td>\n",
       "      <td>Serum Triglycerides</td>\n",
       "      <td>Serum LDL Cholesterol</td>\n",
       "      <td>1884</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>57.5%</td>\n",
       "      <td>68.6%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>19.6%</td>\n",
       "      <td>40.1%</td>\n",
       "      <td>40.3%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>19.6</td>\n",
       "      <td>40.1</td>\n",
       "      <td>40.3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Serum Creatinine</td>\n",
       "      <td>Blood Glucose</td>\n",
       "      <td>C-Reactive Protein Titer</td>\n",
       "      <td>1703</td>\n",
       "      <td>35.8%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>65.6%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>34.4%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>65.6</td>\n",
       "      <td>0.0</td>\n",
       "      <td>34.4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Serum Cholesterol</td>\n",
       "      <td>Serum HDL Cholesterol</td>\n",
       "      <td>Serum LDL Cholesterol</td>\n",
       "      <td>1579</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>37.9%</td>\n",
       "      <td>68.8%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>19.1%</td>\n",
       "      <td>23.7%</td>\n",
       "      <td>57.2%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>19.1</td>\n",
       "      <td>23.7</td>\n",
       "      <td>57.2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Serum Triglycerides</td>\n",
       "      <td>Serum HDL Cholesterol</td>\n",
       "      <td>Serum LDL Cholesterol</td>\n",
       "      <td>1573</td>\n",
       "      <td>57.1%</td>\n",
       "      <td>38.0%</td>\n",
       "      <td>68.6%</td>\n",
       "      <td>18.6%</td>\n",
       "      <td>14.7%</td>\n",
       "      <td>52.6%</td>\n",
       "      <td>32.6%</td>\n",
       "      <td>18.6</td>\n",
       "      <td>14.7</td>\n",
       "      <td>52.6</td>\n",
       "      <td>32.6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Serum Cholesterol</td>\n",
       "      <td>Serum Triglycerides</td>\n",
       "      <td>Serum HDL Cholesterol</td>\n",
       "      <td>1572</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>57.2%</td>\n",
       "      <td>38.1%</td>\n",
       "      <td>0.1%</td>\n",
       "      <td>37.3%</td>\n",
       "      <td>26.1%</td>\n",
       "      <td>36.6%</td>\n",
       "      <td>0.1</td>\n",
       "      <td>37.3</td>\n",
       "      <td>26.1</td>\n",
       "      <td>36.6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Serum Creatinine</td>\n",
       "      <td>Aspartate Aminotransferase (AST)</td>\n",
       "      <td>Alanine Aminotransferase (ALT)</td>\n",
       "      <td>1354</td>\n",
       "      <td>28.9%</td>\n",
       "      <td>10.9%</td>\n",
       "      <td>9.5%</td>\n",
       "      <td>1.7%</td>\n",
       "      <td>62.7%</td>\n",
       "      <td>7.1%</td>\n",
       "      <td>30.2%</td>\n",
       "      <td>1.7</td>\n",
       "      <td>62.7</td>\n",
       "      <td>7.1</td>\n",
       "      <td>30.2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>HbA1c</td>\n",
       "      <td>Serum Creatinine</td>\n",
       "      <td>Blood Glucose</td>\n",
       "      <td>1208</td>\n",
       "      <td>84.8%</td>\n",
       "      <td>35.7%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>11.8%</td>\n",
       "      <td>29.3%</td>\n",
       "      <td>58.9%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>11.8</td>\n",
       "      <td>29.3</td>\n",
       "      <td>58.9</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Total Cholesterol</td>\n",
       "      <td>Triglycerides</td>\n",
       "      <td>LDL Cholesterol</td>\n",
       "      <td>1120</td>\n",
       "      <td>23.1%</td>\n",
       "      <td>58.6%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>34.6%</td>\n",
       "      <td>15.5%</td>\n",
       "      <td>49.9%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>34.6</td>\n",
       "      <td>15.5</td>\n",
       "      <td>49.9</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Aspartate Aminotransferase (AST)</td>\n",
       "      <td>Alanine Aminotransferase (ALT)</td>\n",
       "      <td>Alkaline Phosphatase</td>\n",
       "      <td>1111</td>\n",
       "      <td>13.8%</td>\n",
       "      <td>12.4%</td>\n",
       "      <td>15.5%</td>\n",
       "      <td>2.3%</td>\n",
       "      <td>75.0%</td>\n",
       "      <td>8.9%</td>\n",
       "      <td>16.1%</td>\n",
       "      <td>2.3</td>\n",
       "      <td>75.0</td>\n",
       "      <td>8.9</td>\n",
       "      <td>16.1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Serum Creatinine</td>\n",
       "      <td>Serum Ferritin</td>\n",
       "      <td>Blood Glucose</td>\n",
       "      <td>1101</td>\n",
       "      <td>44.8%</td>\n",
       "      <td>22.3%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>44.9%</td>\n",
       "      <td>9.6%</td>\n",
       "      <td>45.5%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>44.9</td>\n",
       "      <td>9.6</td>\n",
       "      <td>45.5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Serum Creatinine</td>\n",
       "      <td>Blood Glucose</td>\n",
       "      <td>LDL Cholesterol</td>\n",
       "      <td>1088</td>\n",
       "      <td>28.1%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>72.2%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>27.8%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>72.2</td>\n",
       "      <td>0.0</td>\n",
       "      <td>27.8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Serum Creatinine</td>\n",
       "      <td>Total Serum Bilirubin</td>\n",
       "      <td>C-Reactive Protein Titer</td>\n",
       "      <td>1072</td>\n",
       "      <td>37.1%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>65.3%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>34.7%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>65.3</td>\n",
       "      <td>0.0</td>\n",
       "      <td>34.7</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Aspartate Aminotransferase (AST)</td>\n",
       "      <td>Alanine Aminotransferase (ALT)</td>\n",
       "      <td>Total Serum Bilirubin</td>\n",
       "      <td>1060</td>\n",
       "      <td>14.3%</td>\n",
       "      <td>12.1%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>84.2%</td>\n",
       "      <td>6.6%</td>\n",
       "      <td>9.2%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>84.2</td>\n",
       "      <td>6.6</td>\n",
       "      <td>9.2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>TSH</td>\n",
       "      <td>Total Cholesterol</td>\n",
       "      <td>LDL Cholesterol</td>\n",
       "      <td>1048</td>\n",
       "      <td>25.6%</td>\n",
       "      <td>23.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>61.7%</td>\n",
       "      <td>5.1%</td>\n",
       "      <td>33.2%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>61.7</td>\n",
       "      <td>5.1</td>\n",
       "      <td>33.2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Blood Glucose</td>\n",
       "      <td>Total Cholesterol</td>\n",
       "      <td>LDL Cholesterol</td>\n",
       "      <td>1041</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>21.9%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>78.9%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>21.1%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>78.9</td>\n",
       "      <td>0.0</td>\n",
       "      <td>21.1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>TSH</td>\n",
       "      <td>Serum Creatinine</td>\n",
       "      <td>Serum Ferritin</td>\n",
       "      <td>1039</td>\n",
       "      <td>32.4%</td>\n",
       "      <td>43.9%</td>\n",
       "      <td>22.2%</td>\n",
       "      <td>1.9%</td>\n",
       "      <td>34.0%</td>\n",
       "      <td>20.2%</td>\n",
       "      <td>45.8%</td>\n",
       "      <td>1.9</td>\n",
       "      <td>34.0</td>\n",
       "      <td>20.2</td>\n",
       "      <td>45.8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Hepatitis B Surface Antigen</td>\n",
       "      <td>Hepatitis C Antibody</td>\n",
       "      <td>Blood Glucose</td>\n",
       "      <td>1035</td>\n",
       "      <td>0.1%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>99.9%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.1%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>99.9</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Hepatitis B Surface Antigen</td>\n",
       "      <td>HIV Antibody</td>\n",
       "      <td>Blood Glucose</td>\n",
       "      <td>1034</td>\n",
       "      <td>0.1%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>99.9%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.1%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>99.9</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Hepatitis C Antibody</td>\n",
       "      <td>HIV Antibody</td>\n",
       "      <td>Blood Glucose</td>\n",
       "      <td>1034</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>100.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>100.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Total Serum Bilirubin</td>\n",
       "      <td>Blood Glucose</td>\n",
       "      <td>C-Reactive Protein Titer</td>\n",
       "      <td>1031</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>100.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>100.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>TSH</td>\n",
       "      <td>Serum Ferritin</td>\n",
       "      <td>Blood Glucose</td>\n",
       "      <td>1027</td>\n",
       "      <td>29.3%</td>\n",
       "      <td>21.7%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>62.3%</td>\n",
       "      <td>3.8%</td>\n",
       "      <td>33.9%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>62.3</td>\n",
       "      <td>3.8</td>\n",
       "      <td>33.9</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Serum Creatinine</td>\n",
       "      <td>Total Cholesterol</td>\n",
       "      <td>LDL Cholesterol</td>\n",
       "      <td>1024</td>\n",
       "      <td>28.0%</td>\n",
       "      <td>23.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>56.4%</td>\n",
       "      <td>6.7%</td>\n",
       "      <td>36.8%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>56.4</td>\n",
       "      <td>6.7</td>\n",
       "      <td>36.8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>TSH</td>\n",
       "      <td>Serum Creatinine</td>\n",
       "      <td>C-Reactive Protein Titer</td>\n",
       "      <td>1013</td>\n",
       "      <td>29.8%</td>\n",
       "      <td>37.1%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>49.7%</td>\n",
       "      <td>9.7%</td>\n",
       "      <td>40.7%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>49.7</td>\n",
       "      <td>9.7</td>\n",
       "      <td>40.7</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>TSH</td>\n",
       "      <td>Serum Creatinine</td>\n",
       "      <td>LDL Cholesterol</td>\n",
       "      <td>1004</td>\n",
       "      <td>24.8%</td>\n",
       "      <td>29.4%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>55.7%</td>\n",
       "      <td>5.6%</td>\n",
       "      <td>38.7%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>55.7</td>\n",
       "      <td>5.6</td>\n",
       "      <td>38.7</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Blood Urea Nitrogen</td>\n",
       "      <td>Serum Creatinine</td>\n",
       "      <td>Blood Glucose</td>\n",
       "      <td>1003</td>\n",
       "      <td>73.0%</td>\n",
       "      <td>34.2%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>17.4%</td>\n",
       "      <td>18.4%</td>\n",
       "      <td>64.1%</td>\n",
       "      <td>0.0</td>\n",
       "      <td>17.4</td>\n",
       "      <td>18.4</td>\n",
       "      <td>64.1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                              Test 1                            Test 2  \\\n",
       "0        Hepatitis B Surface Antigen              Hepatitis C Antibody   \n",
       "1                                TSH                  Serum Creatinine   \n",
       "2                   Serum Creatinine             Total Serum Bilirubin   \n",
       "3                                TSH                  Serum Creatinine   \n",
       "4                                TSH             Total Serum Bilirubin   \n",
       "5                  Serum Cholesterol               Serum Triglycerides   \n",
       "6                   Serum Creatinine                     Blood Glucose   \n",
       "7                  Serum Cholesterol             Serum HDL Cholesterol   \n",
       "8                Serum Triglycerides             Serum HDL Cholesterol   \n",
       "9                  Serum Cholesterol               Serum Triglycerides   \n",
       "10                  Serum Creatinine  Aspartate Aminotransferase (AST)   \n",
       "11                             HbA1c                  Serum Creatinine   \n",
       "12                 Total Cholesterol                     Triglycerides   \n",
       "13  Aspartate Aminotransferase (AST)    Alanine Aminotransferase (ALT)   \n",
       "14                  Serum Creatinine                    Serum Ferritin   \n",
       "15                  Serum Creatinine                     Blood Glucose   \n",
       "16                  Serum Creatinine             Total Serum Bilirubin   \n",
       "17  Aspartate Aminotransferase (AST)    Alanine Aminotransferase (ALT)   \n",
       "18                               TSH                 Total Cholesterol   \n",
       "19                     Blood Glucose                 Total Cholesterol   \n",
       "20                               TSH                  Serum Creatinine   \n",
       "21       Hepatitis B Surface Antigen              Hepatitis C Antibody   \n",
       "22       Hepatitis B Surface Antigen                      HIV Antibody   \n",
       "23              Hepatitis C Antibody                      HIV Antibody   \n",
       "24             Total Serum Bilirubin                     Blood Glucose   \n",
       "25                               TSH                    Serum Ferritin   \n",
       "26                  Serum Creatinine                 Total Cholesterol   \n",
       "27                               TSH                  Serum Creatinine   \n",
       "28                               TSH                  Serum Creatinine   \n",
       "29               Blood Urea Nitrogen                  Serum Creatinine   \n",
       "\n",
       "                            Test 3  Total Patients Test 1 Abnormal %  \\\n",
       "0                     HIV Antibody            4843              0.2%   \n",
       "1                    Blood Glucose            2898             28.3%   \n",
       "2                    Blood Glucose            2880             36.7%   \n",
       "3            Total Serum Bilirubin            2171             27.2%   \n",
       "4                    Blood Glucose            2036             27.0%   \n",
       "5            Serum LDL Cholesterol            1884              0.0%   \n",
       "6         C-Reactive Protein Titer            1703             35.8%   \n",
       "7            Serum LDL Cholesterol            1579              0.0%   \n",
       "8            Serum LDL Cholesterol            1573             57.1%   \n",
       "9            Serum HDL Cholesterol            1572              0.0%   \n",
       "10  Alanine Aminotransferase (ALT)            1354             28.9%   \n",
       "11                   Blood Glucose            1208             84.8%   \n",
       "12                 LDL Cholesterol            1120             23.1%   \n",
       "13            Alkaline Phosphatase            1111             13.8%   \n",
       "14                   Blood Glucose            1101             44.8%   \n",
       "15                 LDL Cholesterol            1088             28.1%   \n",
       "16        C-Reactive Protein Titer            1072             37.1%   \n",
       "17           Total Serum Bilirubin            1060             14.3%   \n",
       "18                 LDL Cholesterol            1048             25.6%   \n",
       "19                 LDL Cholesterol            1041              0.0%   \n",
       "20                  Serum Ferritin            1039             32.4%   \n",
       "21                   Blood Glucose            1035              0.1%   \n",
       "22                   Blood Glucose            1034              0.1%   \n",
       "23                   Blood Glucose            1034              0.0%   \n",
       "24        C-Reactive Protein Titer            1031              0.0%   \n",
       "25                   Blood Glucose            1027             29.3%   \n",
       "26                 LDL Cholesterol            1024             28.0%   \n",
       "27        C-Reactive Protein Titer            1013             29.8%   \n",
       "28                 LDL Cholesterol            1004             24.8%   \n",
       "29                   Blood Glucose            1003             73.0%   \n",
       "\n",
       "   Test 2 Abnormal % Test 3 Abnormal % All 3 Abnormal % All 3 Normal %  \\\n",
       "0               0.0%              0.0%             0.0%          99.8%   \n",
       "1              36.8%              0.0%             0.0%          48.9%   \n",
       "2               0.0%              0.0%             0.0%          64.0%   \n",
       "3              37.6%              0.0%             0.0%          48.5%   \n",
       "4               0.0%              0.0%             0.0%          78.0%   \n",
       "5              57.5%             68.6%             0.0%          19.6%   \n",
       "6               0.0%              0.0%             0.0%          65.6%   \n",
       "7              37.9%             68.8%             0.0%          19.1%   \n",
       "8              38.0%             68.6%            18.6%          14.7%   \n",
       "9              57.2%             38.1%             0.1%          37.3%   \n",
       "10             10.9%              9.5%             1.7%          62.7%   \n",
       "11             35.7%              0.0%             0.0%          11.8%   \n",
       "12             58.6%              0.0%             0.0%          34.6%   \n",
       "13             12.4%             15.5%             2.3%          75.0%   \n",
       "14             22.3%              0.0%             0.0%          44.9%   \n",
       "15              0.0%              0.0%             0.0%          72.2%   \n",
       "16              0.0%              0.0%             0.0%          65.3%   \n",
       "17             12.1%              0.0%             0.0%          84.2%   \n",
       "18             23.0%              0.0%             0.0%          61.7%   \n",
       "19             21.9%              0.0%             0.0%          78.9%   \n",
       "20             43.9%             22.2%             1.9%          34.0%   \n",
       "21              0.0%              0.0%             0.0%          99.9%   \n",
       "22              0.0%              0.0%             0.0%          99.9%   \n",
       "23              0.0%              0.0%             0.0%         100.0%   \n",
       "24              0.0%              0.0%             0.0%         100.0%   \n",
       "25             21.7%              0.0%             0.0%          62.3%   \n",
       "26             23.0%              0.0%             0.0%          56.4%   \n",
       "27             37.1%              0.0%             0.0%          49.7%   \n",
       "28             29.4%              0.0%             0.0%          55.7%   \n",
       "29             34.2%              0.0%             0.0%          17.4%   \n",
       "\n",
       "   2+ Abnormal % 1 Abnormal %  All_Abnormal_Numeric  All_Normal_Numeric  \\\n",
       "0           0.0%         0.2%                   0.0                99.8   \n",
       "1           8.5%        42.6%                   0.0                48.9   \n",
       "2           0.0%        36.0%                   0.0                64.0   \n",
       "3           7.9%        43.6%                   0.0                48.5   \n",
       "4           0.0%        22.0%                   0.0                78.0   \n",
       "5          40.1%        40.3%                   0.0                19.6   \n",
       "6           0.0%        34.4%                   0.0                65.6   \n",
       "7          23.7%        57.2%                   0.0                19.1   \n",
       "8          52.6%        32.6%                  18.6                14.7   \n",
       "9          26.1%        36.6%                   0.1                37.3   \n",
       "10          7.1%        30.2%                   1.7                62.7   \n",
       "11         29.3%        58.9%                   0.0                11.8   \n",
       "12         15.5%        49.9%                   0.0                34.6   \n",
       "13          8.9%        16.1%                   2.3                75.0   \n",
       "14          9.6%        45.5%                   0.0                44.9   \n",
       "15          0.0%        27.8%                   0.0                72.2   \n",
       "16          0.0%        34.7%                   0.0                65.3   \n",
       "17          6.6%         9.2%                   0.0                84.2   \n",
       "18          5.1%        33.2%                   0.0                61.7   \n",
       "19          0.0%        21.1%                   0.0                78.9   \n",
       "20         20.2%        45.8%                   1.9                34.0   \n",
       "21          0.0%         0.1%                   0.0                99.9   \n",
       "22          0.0%         0.1%                   0.0                99.9   \n",
       "23          0.0%         0.0%                   0.0               100.0   \n",
       "24          0.0%         0.0%                   0.0               100.0   \n",
       "25          3.8%        33.9%                   0.0                62.3   \n",
       "26          6.7%        36.8%                   0.0                56.4   \n",
       "27          9.7%        40.7%                   0.0                49.7   \n",
       "28          5.6%        38.7%                   0.0                55.7   \n",
       "29         18.4%        64.1%                   0.0                17.4   \n",
       "\n",
       "    Two_Plus_Abnormal_Numeric  One_Abnormal_Numeric  \n",
       "0                         0.0                   0.2  \n",
       "1                         8.5                  42.6  \n",
       "2                         0.0                  36.0  \n",
       "3                         7.9                  43.6  \n",
       "4                         0.0                  22.0  \n",
       "5                        40.1                  40.3  \n",
       "6                         0.0                  34.4  \n",
       "7                        23.7                  57.2  \n",
       "8                        52.6                  32.6  \n",
       "9                        26.1                  36.6  \n",
       "10                        7.1                  30.2  \n",
       "11                       29.3                  58.9  \n",
       "12                       15.5                  49.9  \n",
       "13                        8.9                  16.1  \n",
       "14                        9.6                  45.5  \n",
       "15                        0.0                  27.8  \n",
       "16                        0.0                  34.7  \n",
       "17                        6.6                   9.2  \n",
       "18                        5.1                  33.2  \n",
       "19                        0.0                  21.1  \n",
       "20                       20.2                  45.8  \n",
       "21                        0.0                   0.1  \n",
       "22                        0.0                   0.1  \n",
       "23                        0.0                   0.0  \n",
       "24                        0.0                   0.0  \n",
       "25                        3.8                  33.9  \n",
       "26                        6.7                  36.8  \n",
       "27                        9.7                  40.7  \n",
       "28                        5.6                  38.7  \n",
       "29                       18.4                  64.1  "
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "enhanced_summary_df"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "52194415",
   "metadata": {},
   "source": [
    "# Criteria for Selecting Best Three-Test Combinations for Classification Model\n",
    "\n",
    "## Primary Selection Criteria\n",
    "\n",
    "When selecting the best three-test combinations for building a classification model, we should consider several key factors:\n",
    "\n",
    "### 1. **Statistical Significance & Sample Size**\n",
    "- **Minimum patient count**: â‰¥1000 patients for reliable model training\n",
    "- **Balanced representation**: Adequate samples across different outcome patterns\n",
    "\n",
    "### 2. **Outcome Distribution Quality**\n",
    "- **Balanced abnormal rates**: Individual test abnormal rates between 15-70% (avoiding extreme skews)\n",
    "- **Meaningful variation**: Good mix of normal/abnormal combinations across patients\n",
    "- **Clinical relevance**: Combinations that represent real-world diagnostic scenarios\n",
    "\n",
    "### 3. **Predictive Potential**\n",
    "- **Moderate correlation**: 2+ abnormal rates between 20-50% (too low = independent tests, too high = redundant)\n",
    "- **Discriminative power**: Clear patterns that can separate risk groups\n",
    "- **Complementary information**: Tests that provide different diagnostic insights\n",
    "\n",
    "### 4. **Clinical Interpretability**\n",
    "- **Related organ systems**: Tests that logically group together (e.g., liver function, lipid panel, kidney function)\n",
    "- **Common co-testing**: Combinations frequently ordered together in clinical practice\n",
    "- **Actionable insights**: Results that can inform treatment decisions\n",
    "\n",
    "## Recommended Top Combinations for Classification\n",
    "\n",
    "Based on the analysis, the best candidates would likely be:\n",
    "\n",
    "1. **Serum Triglycerides + Serum HDL Cholesterol + Serum LDL Cholesterol** (1573 patients)\n",
    "   - Complete lipid panel with high clinical relevance\n",
    "   - Good balance of abnormal rates (52.6% with 2+ abnormal)\n",
    "\n",
    "2. **HbA1c + Serum Creatinine + Blood Glucose** (1208 patients)\n",
    "   - Diabetes/kidney function assessment\n",
    "   - High predictive value for metabolic disorders\n",
    "\n",
    "3. **Aspartate Aminotransferase (AST) + Alanine Aminotransferase (ALT) + Alkaline Phosphatase** (1111 patients)\n",
    "   - Liver function panel\n",
    "   - Clinically coherent combination\n",
    "\n",
    "4. **TSH + Serum Creatinine + Serum Ferritin** (1039 patients)\n",
    "   - Multi-system assessment (thyroid, kidney, iron status)\n",
    "   - Good balance of outcomes\n",
    "\n",
    "These combinations offer the best balance of statistical power, clinical relevance, and predictive potential for classification modeling."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "09f72d36",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ğŸ¯ SELECTION CRITERIA FOR CLASSIFICATION MODEL\n",
      "======================================================================\n",
      "\n",
      "ğŸ“Š SCORING CRITERIA:\n",
      "1. Patient Count Score (25%): Higher patient count = better statistical power\n",
      "2. Balance Score (25%): Balanced abnormal rates (15-70%) across tests\n",
      "3. Predictive Score (25%): Good 2+ abnormal rate (20-50%) for discrimination\n",
      "4. Clinical Relevance Score (25%): Related tests that are commonly ordered together\n",
      "\n",
      "ğŸ† TOP CLASSIFICATION MODEL CANDIDATES\n",
      "====================================================================================================\n",
      "Selected 5 combinations with Overall Score â‰¥ 70\n",
      "\n",
      "1. Serum Triglycerides + Serum HDL Cholesterol + Serum LDL Cholesterol\n",
      "   ğŸ“Š Overall Score: 82.1/100\n",
      "   ğŸ‘¥ Patients: 1,573 (Score: 32.5)\n",
      "   âš–ï¸  Balance: 100.0 (Abnormal rates: 57.1% | 38.0% | 68.6%)\n",
      "   ğŸ¯ Predictive: 96.1 (2+ Abnormal: 52.6%)\n",
      "   ğŸ¥ Clinical: 100.0\n",
      "\n",
      "2. Serum Cholesterol + Serum Triglycerides + Serum LDL Cholesterol\n",
      "   ğŸ“Š Overall Score: 76.4/100\n",
      "   ğŸ‘¥ Patients: 1,884 (Score: 38.9)\n",
      "   âš–ï¸  Balance: 66.7 (Abnormal rates: 0.0% | 57.5% | 68.6%)\n",
      "   ğŸ¯ Predictive: 100.0 (2+ Abnormal: 40.1%)\n",
      "   ğŸ¥ Clinical: 100.0\n",
      "\n",
      "3. Serum Cholesterol + Serum HDL Cholesterol + Serum LDL Cholesterol\n",
      "   ğŸ“Š Overall Score: 74.8/100\n",
      "   ğŸ‘¥ Patients: 1,579 (Score: 32.6)\n",
      "   âš–ï¸  Balance: 66.7 (Abnormal rates: 0.0% | 37.9% | 68.8%)\n",
      "   ğŸ¯ Predictive: 100.0 (2+ Abnormal: 23.7%)\n",
      "   ğŸ¥ Clinical: 100.0\n",
      "\n",
      "4. Serum Cholesterol + Serum Triglycerides + Serum HDL Cholesterol\n",
      "   ğŸ“Š Overall Score: 74.8/100\n",
      "   ğŸ‘¥ Patients: 1,572 (Score: 32.5)\n",
      "   âš–ï¸  Balance: 66.7 (Abnormal rates: 0.0% | 57.2% | 38.1%)\n",
      "   ğŸ¯ Predictive: 100.0 (2+ Abnormal: 26.1%)\n",
      "   ğŸ¥ Clinical: 100.0\n",
      "\n",
      "5. TSH + Serum Creatinine + Serum Ferritin\n",
      "   ğŸ“Š Overall Score: 74.1/100\n",
      "   ğŸ‘¥ Patients: 1,039 (Score: 21.5)\n",
      "   âš–ï¸  Balance: 100.0 (Abnormal rates: 32.4% | 43.9% | 22.2%)\n",
      "   ğŸ¯ Predictive: 100.0 (2+ Abnormal: 20.2%)\n",
      "   ğŸ¥ Clinical: 75.0\n",
      "\n",
      "ğŸ“ˆ CANDIDATE SUMMARY:\n",
      "Total Candidates: 5\n",
      "Average Overall Score: 76.4\n",
      "Average Patient Count: 1529\n",
      "Score Range: 74.1 - 82.1\n",
      "\n",
      "ğŸ“‹ CLASSIFICATION_3_TEST_CANDIDATE DATAFRAME:\n",
      "Shape: (5, 23)\n",
      "Columns: ['Test 1', 'Test 2', 'Test 3', 'Total Patients', 'Test 1 Abnormal %', 'Test 2 Abnormal %', 'Test 3 Abnormal %', 'All 3 Abnormal %', 'All 3 Normal %', '2+ Abnormal %', '1 Abnormal %', 'All_Abnormal_Numeric', 'All_Normal_Numeric', 'Two_Plus_Abnormal_Numeric', 'One_Abnormal_Numeric', 'Test_1_Abnormal_Numeric', 'Test_2_Abnormal_Numeric', 'Test_3_Abnormal_Numeric', 'Patient_Count_Score', 'Balance_Score', 'Predictive_Score', 'Clinical_Score', 'Overall_Score']\n",
      "\n",
      "ğŸ’¾ Results saved to '../model_data_insight/classification_3_test_candidates.csv'\n",
      "\n",
      "ğŸ¯ RECOMMENDED TOP 5 FOR CLASSIFICATION MODEL:\n",
      "================================================================================\n",
      "1. Serum Triglycerides + Serum HDL Cholesterol + Serum LDL Cholesterol\n",
      "   Score: 82.1 | Patients: 1,573 | 2+ Abnormal: 52.6%\n",
      "2. Serum Cholesterol + Serum Triglycerides + Serum LDL Cholesterol\n",
      "   Score: 76.4 | Patients: 1,884 | 2+ Abnormal: 40.1%\n",
      "3. Serum Cholesterol + Serum HDL Cholesterol + Serum LDL Cholesterol\n",
      "   Score: 74.8 | Patients: 1,579 | 2+ Abnormal: 23.7%\n",
      "4. Serum Cholesterol + Serum Triglycerides + Serum HDL Cholesterol\n",
      "   Score: 74.8 | Patients: 1,572 | 2+ Abnormal: 26.1%\n",
      "5. TSH + Serum Creatinine + Serum Ferritin\n",
      "   Score: 74.1 | Patients: 1,039 | 2+ Abnormal: 20.2%\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Test 1</th>\n",
       "      <th>Test 2</th>\n",
       "      <th>Test 3</th>\n",
       "      <th>Total Patients</th>\n",
       "      <th>Test 1 Abnormal %</th>\n",
       "      <th>Test 2 Abnormal %</th>\n",
       "      <th>Test 3 Abnormal %</th>\n",
       "      <th>All 3 Abnormal %</th>\n",
       "      <th>All 3 Normal %</th>\n",
       "      <th>2+ Abnormal %</th>\n",
       "      <th>...</th>\n",
       "      <th>Two_Plus_Abnormal_Numeric</th>\n",
       "      <th>One_Abnormal_Numeric</th>\n",
       "      <th>Test_1_Abnormal_Numeric</th>\n",
       "      <th>Test_2_Abnormal_Numeric</th>\n",
       "      <th>Test_3_Abnormal_Numeric</th>\n",
       "      <th>Patient_Count_Score</th>\n",
       "      <th>Balance_Score</th>\n",
       "      <th>Predictive_Score</th>\n",
       "      <th>Clinical_Score</th>\n",
       "      <th>Overall_Score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Serum Triglycerides</td>\n",
       "      <td>Serum HDL Cholesterol</td>\n",
       "      <td>Serum LDL Cholesterol</td>\n",
       "      <td>1573</td>\n",
       "      <td>57.1%</td>\n",
       "      <td>38.0%</td>\n",
       "      <td>68.6%</td>\n",
       "      <td>18.6%</td>\n",
       "      <td>14.7%</td>\n",
       "      <td>52.6%</td>\n",
       "      <td>...</td>\n",
       "      <td>52.6</td>\n",
       "      <td>32.6</td>\n",
       "      <td>57.1</td>\n",
       "      <td>38.0</td>\n",
       "      <td>68.6</td>\n",
       "      <td>32.479868</td>\n",
       "      <td>100.000000</td>\n",
       "      <td>96.1</td>\n",
       "      <td>100</td>\n",
       "      <td>82.144967</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Serum Cholesterol</td>\n",
       "      <td>Serum Triglycerides</td>\n",
       "      <td>Serum LDL Cholesterol</td>\n",
       "      <td>1884</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>57.5%</td>\n",
       "      <td>68.6%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>19.6%</td>\n",
       "      <td>40.1%</td>\n",
       "      <td>...</td>\n",
       "      <td>40.1</td>\n",
       "      <td>40.3</td>\n",
       "      <td>0.0</td>\n",
       "      <td>57.5</td>\n",
       "      <td>68.6</td>\n",
       "      <td>38.901507</td>\n",
       "      <td>66.666667</td>\n",
       "      <td>100.0</td>\n",
       "      <td>100</td>\n",
       "      <td>76.392043</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Serum Cholesterol</td>\n",
       "      <td>Serum HDL Cholesterol</td>\n",
       "      <td>Serum LDL Cholesterol</td>\n",
       "      <td>1579</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>37.9%</td>\n",
       "      <td>68.8%</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>19.1%</td>\n",
       "      <td>23.7%</td>\n",
       "      <td>...</td>\n",
       "      <td>23.7</td>\n",
       "      <td>57.2</td>\n",
       "      <td>0.0</td>\n",
       "      <td>37.9</td>\n",
       "      <td>68.8</td>\n",
       "      <td>32.603758</td>\n",
       "      <td>66.666667</td>\n",
       "      <td>100.0</td>\n",
       "      <td>100</td>\n",
       "      <td>74.817606</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Serum Cholesterol</td>\n",
       "      <td>Serum Triglycerides</td>\n",
       "      <td>Serum HDL Cholesterol</td>\n",
       "      <td>1572</td>\n",
       "      <td>0.0%</td>\n",
       "      <td>57.2%</td>\n",
       "      <td>38.1%</td>\n",
       "      <td>0.1%</td>\n",
       "      <td>37.3%</td>\n",
       "      <td>26.1%</td>\n",
       "      <td>...</td>\n",
       "      <td>26.1</td>\n",
       "      <td>36.6</td>\n",
       "      <td>0.0</td>\n",
       "      <td>57.2</td>\n",
       "      <td>38.1</td>\n",
       "      <td>32.459219</td>\n",
       "      <td>66.666667</td>\n",
       "      <td>100.0</td>\n",
       "      <td>100</td>\n",
       "      <td>74.781472</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>TSH</td>\n",
       "      <td>Serum Creatinine</td>\n",
       "      <td>Serum Ferritin</td>\n",
       "      <td>1039</td>\n",
       "      <td>32.4%</td>\n",
       "      <td>43.9%</td>\n",
       "      <td>22.2%</td>\n",
       "      <td>1.9%</td>\n",
       "      <td>34.0%</td>\n",
       "      <td>20.2%</td>\n",
       "      <td>...</td>\n",
       "      <td>20.2</td>\n",
       "      <td>45.8</td>\n",
       "      <td>32.4</td>\n",
       "      <td>43.9</td>\n",
       "      <td>22.2</td>\n",
       "      <td>21.453644</td>\n",
       "      <td>100.000000</td>\n",
       "      <td>100.0</td>\n",
       "      <td>75</td>\n",
       "      <td>74.113411</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows Ã— 23 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                Test 1                 Test 2                 Test 3  \\\n",
       "0  Serum Triglycerides  Serum HDL Cholesterol  Serum LDL Cholesterol   \n",
       "1    Serum Cholesterol    Serum Triglycerides  Serum LDL Cholesterol   \n",
       "2    Serum Cholesterol  Serum HDL Cholesterol  Serum LDL Cholesterol   \n",
       "3    Serum Cholesterol    Serum Triglycerides  Serum HDL Cholesterol   \n",
       "4                  TSH       Serum Creatinine         Serum Ferritin   \n",
       "\n",
       "   Total Patients Test 1 Abnormal % Test 2 Abnormal % Test 3 Abnormal %  \\\n",
       "0            1573             57.1%             38.0%             68.6%   \n",
       "1            1884              0.0%             57.5%             68.6%   \n",
       "2            1579              0.0%             37.9%             68.8%   \n",
       "3            1572              0.0%             57.2%             38.1%   \n",
       "4            1039             32.4%             43.9%             22.2%   \n",
       "\n",
       "  All 3 Abnormal % All 3 Normal % 2+ Abnormal %  ...  \\\n",
       "0            18.6%          14.7%         52.6%  ...   \n",
       "1             0.0%          19.6%         40.1%  ...   \n",
       "2             0.0%          19.1%         23.7%  ...   \n",
       "3             0.1%          37.3%         26.1%  ...   \n",
       "4             1.9%          34.0%         20.2%  ...   \n",
       "\n",
       "  Two_Plus_Abnormal_Numeric  One_Abnormal_Numeric  Test_1_Abnormal_Numeric  \\\n",
       "0                      52.6                  32.6                     57.1   \n",
       "1                      40.1                  40.3                      0.0   \n",
       "2                      23.7                  57.2                      0.0   \n",
       "3                      26.1                  36.6                      0.0   \n",
       "4                      20.2                  45.8                     32.4   \n",
       "\n",
       "   Test_2_Abnormal_Numeric  Test_3_Abnormal_Numeric  Patient_Count_Score  \\\n",
       "0                     38.0                     68.6            32.479868   \n",
       "1                     57.5                     68.6            38.901507   \n",
       "2                     37.9                     68.8            32.603758   \n",
       "3                     57.2                     38.1            32.459219   \n",
       "4                     43.9                     22.2            21.453644   \n",
       "\n",
       "   Balance_Score  Predictive_Score  Clinical_Score  Overall_Score  \n",
       "0     100.000000              96.1             100      82.144967  \n",
       "1      66.666667             100.0             100      76.392043  \n",
       "2      66.666667             100.0             100      74.817606  \n",
       "3      66.666667             100.0             100      74.781472  \n",
       "4     100.000000             100.0              75      74.113411  \n",
       "\n",
       "[5 rows x 23 columns]"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Define selection criteria for the best three-test combinations for classification modeling\n",
    "\n",
    "print(\"ğŸ¯ SELECTION CRITERIA FOR CLASSIFICATION MODEL\")\n",
    "print(\"=\"*70)\n",
    "\n",
    "# Create a copy of the enhanced summary dataframe for scoring\n",
    "classification_candidates = enhanced_summary_df.copy()\n",
    "\n",
    "# Convert percentage strings to numeric values for calculations\n",
    "classification_candidates['Test_1_Abnormal_Numeric'] = classification_candidates['Test 1 Abnormal %'].str.rstrip('%').astype(float)\n",
    "classification_candidates['Test_2_Abnormal_Numeric'] = classification_candidates['Test 2 Abnormal %'].str.rstrip('%').astype(float)\n",
    "classification_candidates['Test_3_Abnormal_Numeric'] = classification_candidates['Test 3 Abnormal %'].str.rstrip('%').astype(float)\n",
    "\n",
    "# Calculate scoring criteria\n",
    "print(\"\\nğŸ“Š SCORING CRITERIA:\")\n",
    "print(\"1. Patient Count Score (25%): Higher patient count = better statistical power\")\n",
    "print(\"2. Balance Score (25%): Balanced abnormal rates (15-70%) across tests\")\n",
    "print(\"3. Predictive Score (25%): Good 2+ abnormal rate (20-50%) for discrimination\")\n",
    "print(\"4. Clinical Relevance Score (25%): Related tests that are commonly ordered together\")\n",
    "\n",
    "# 1. Patient Count Score (normalized 0-100)\n",
    "max_patients = classification_candidates['Total Patients'].max()\n",
    "classification_candidates['Patient_Count_Score'] = (classification_candidates['Total Patients'] / max_patients) * 100\n",
    "\n",
    "# 2. Balance Score: Penalize extreme abnormal rates (prefer 15-70% range)\n",
    "def calculate_balance_score(test1_pct, test2_pct, test3_pct):\n",
    "    \"\"\"Calculate balance score based on how well abnormal rates fall within optimal range\"\"\"\n",
    "    optimal_min, optimal_max = 15, 70\n",
    "    \n",
    "    scores = []\n",
    "    for pct in [test1_pct, test2_pct, test3_pct]:\n",
    "        if optimal_min <= pct <= optimal_max:\n",
    "            # Perfect score for optimal range\n",
    "            score = 100\n",
    "        elif pct < optimal_min:\n",
    "            # Penalize low abnormal rates\n",
    "            score = (pct / optimal_min) * 100\n",
    "        else:\n",
    "            # Penalize very high abnormal rates\n",
    "            score = max(0, 100 - ((pct - optimal_max) * 2))\n",
    "        scores.append(score)\n",
    "    \n",
    "    return sum(scores) / 3  # Average of the three test scores\n",
    "\n",
    "classification_candidates['Balance_Score'] = classification_candidates.apply(\n",
    "    lambda row: calculate_balance_score(\n",
    "        row['Test_1_Abnormal_Numeric'], \n",
    "        row['Test_2_Abnormal_Numeric'], \n",
    "        row['Test_3_Abnormal_Numeric']\n",
    "    ), axis=1\n",
    ")\n",
    "\n",
    "# 3. Predictive Score: Optimal 2+ abnormal rate for discrimination\n",
    "def calculate_predictive_score(two_plus_abnormal_pct):\n",
    "    \"\"\"Calculate predictive score based on 2+ abnormal rate\"\"\"\n",
    "    optimal_min, optimal_max = 20, 50\n",
    "    \n",
    "    if optimal_min <= two_plus_abnormal_pct <= optimal_max:\n",
    "        return 100\n",
    "    elif two_plus_abnormal_pct < optimal_min:\n",
    "        return (two_plus_abnormal_pct / optimal_min) * 100\n",
    "    else:\n",
    "        return max(0, 100 - ((two_plus_abnormal_pct - optimal_max) * 1.5))\n",
    "\n",
    "classification_candidates['Predictive_Score'] = classification_candidates['Two_Plus_Abnormal_Numeric'].apply(\n",
    "    calculate_predictive_score\n",
    ")\n",
    "\n",
    "# 4. Clinical Relevance Score: Based on logical test groupings\n",
    "def calculate_clinical_score(test1, test2, test3):\n",
    "    \"\"\"Calculate clinical relevance score based on test relationships\"\"\"\n",
    "    \n",
    "    # Define clinical test groups\n",
    "    lipid_tests = ['Serum Cholesterol', 'Serum Triglycerides', 'Serum HDL Cholesterol', \n",
    "                   'Serum LDL Cholesterol', 'Total Cholesterol', 'Triglycerides', 'LDL Cholesterol']\n",
    "    \n",
    "    liver_tests = ['Aspartate Aminotransferase (AST)', 'Alanine Aminotransferase (ALT)', \n",
    "                   'Alkaline Phosphatase', 'Total Serum Bilirubin']\n",
    "    \n",
    "    kidney_tests = ['Serum Creatinine', 'Blood Urea Nitrogen']\n",
    "    \n",
    "    diabetes_tests = ['HbA1c', 'Blood Glucose', 'Blood Sugar', 'Glucose']\n",
    "    \n",
    "    thyroid_tests = ['TSH', 'Free T4']\n",
    "    \n",
    "    infection_tests = ['Hepatitis B Surface Antigen', 'Hepatitis C Antibody', 'HIV Antibody']\n",
    "    \n",
    "    iron_tests = ['S.Iron', 'Serum Ferritin']\n",
    "    \n",
    "    tests = [test1, test2, test3]\n",
    "    \n",
    "    # Check for complete panels (highest score)\n",
    "    lipid_count = sum(1 for test in tests if test in lipid_tests)\n",
    "    liver_count = sum(1 for test in tests if test in liver_tests)\n",
    "    infection_count = sum(1 for test in tests if test in infection_tests)\n",
    "    \n",
    "    if lipid_count == 3:\n",
    "        return 100  # Complete lipid panel\n",
    "    elif liver_count == 3:\n",
    "        return 100  # Complete liver panel\n",
    "    elif infection_count == 3:\n",
    "        return 95   # Complete infection screening\n",
    "    elif lipid_count == 2:\n",
    "        return 85   # Partial lipid panel\n",
    "    elif liver_count == 2:\n",
    "        return 85   # Partial liver panel\n",
    "    \n",
    "    # Check for logical combinations\n",
    "    diabetes_kidney = sum(1 for test in tests if test in diabetes_tests) + sum(1 for test in tests if test in kidney_tests)\n",
    "    if diabetes_kidney >= 2:\n",
    "        return 80   # Diabetes/kidney function assessment\n",
    "    \n",
    "    thyroid_general = sum(1 for test in tests if test in thyroid_tests) + sum(1 for test in tests if test in kidney_tests + diabetes_tests)\n",
    "    if thyroid_general >= 2:\n",
    "        return 75   # Thyroid with general health markers\n",
    "    \n",
    "    # Default score for unrelated tests\n",
    "    return 50\n",
    "\n",
    "classification_candidates['Clinical_Score'] = classification_candidates.apply(\n",
    "    lambda row: calculate_clinical_score(row['Test 1'], row['Test 2'], row['Test 3']), axis=1\n",
    ")\n",
    "\n",
    "# Calculate overall score (weighted average)\n",
    "classification_candidates['Overall_Score'] = (\n",
    "    classification_candidates['Patient_Count_Score'] * 0.25 +\n",
    "    classification_candidates['Balance_Score'] * 0.25 +\n",
    "    classification_candidates['Predictive_Score'] * 0.25 +\n",
    "    classification_candidates['Clinical_Score'] * 0.25\n",
    ")\n",
    "\n",
    "# Sort by overall score\n",
    "classification_candidates = classification_candidates.sort_values('Overall_Score', ascending=False)\n",
    "\n",
    "# Select top candidates (those with overall score > 70)\n",
    "classification_3_test_candidate = classification_candidates[\n",
    "    classification_candidates['Overall_Score'] >= 70\n",
    "].reset_index(drop=True)\n",
    "\n",
    "print(f\"\\nğŸ† TOP CLASSIFICATION MODEL CANDIDATES\")\n",
    "print(\"=\"*100)\n",
    "print(f\"Selected {len(classification_3_test_candidate)} combinations with Overall Score â‰¥ 70\")\n",
    "\n",
    "# Display detailed results\n",
    "for i, (_, row) in enumerate(classification_3_test_candidate.head(10).iterrows(), 1):\n",
    "    print(f\"\\n{i}. {row['Test 1']} + {row['Test 2']} + {row['Test 3']}\")\n",
    "    print(f\"   ğŸ“Š Overall Score: {row['Overall_Score']:.1f}/100\")\n",
    "    print(f\"   ğŸ‘¥ Patients: {row['Total Patients']:,} (Score: {row['Patient_Count_Score']:.1f})\")\n",
    "    print(f\"   âš–ï¸  Balance: {row['Balance_Score']:.1f} (Abnormal rates: {row['Test 1 Abnormal %']} | {row['Test 2 Abnormal %']} | {row['Test 3 Abnormal %']})\")\n",
    "    print(f\"   ğŸ¯ Predictive: {row['Predictive_Score']:.1f} (2+ Abnormal: {row['2+ Abnormal %']})\")\n",
    "    print(f\"   ğŸ¥ Clinical: {row['Clinical_Score']:.1f}\")\n",
    "\n",
    "# Show summary statistics\n",
    "print(f\"\\nğŸ“ˆ CANDIDATE SUMMARY:\")\n",
    "print(f\"Total Candidates: {len(classification_3_test_candidate)}\")\n",
    "print(f\"Average Overall Score: {classification_3_test_candidate['Overall_Score'].mean():.1f}\")\n",
    "print(f\"Average Patient Count: {classification_3_test_candidate['Total Patients'].mean():.0f}\")\n",
    "print(f\"Score Range: {classification_3_test_candidate['Overall_Score'].min():.1f} - {classification_3_test_candidate['Overall_Score'].max():.1f}\")\n",
    "\n",
    "# Display the final candidate dataframe structure\n",
    "print(f\"\\nğŸ“‹ CLASSIFICATION_3_TEST_CANDIDATE DATAFRAME:\")\n",
    "print(f\"Shape: {classification_3_test_candidate.shape}\")\n",
    "print(f\"Columns: {classification_3_test_candidate.columns.tolist()}\")\n",
    "\n",
    "# Save the results\n",
    "classification_3_test_candidate.to_csv('../model_data_insight/classification_3_test_candidates.csv', index=False)\n",
    "print(f\"\\nğŸ’¾ Results saved to '../model_data_insight/classification_3_test_candidates.csv'\")\n",
    "\n",
    "# Show recommended top 5 for immediate use\n",
    "print(f\"\\nğŸ¯ RECOMMENDED TOP 5 FOR CLASSIFICATION MODEL:\")\n",
    "print(\"=\"*80)\n",
    "top_5_recommended = classification_3_test_candidate.head(5)\n",
    "for i, (_, row) in enumerate(top_5_recommended.iterrows(), 1):\n",
    "    print(f\"{i}. {row['Test 1']} + {row['Test 2']} + {row['Test 3']}\")\n",
    "    print(f\"   Score: {row['Overall_Score']:.1f} | Patients: {row['Total Patients']:,} | 2+ Abnormal: {row['2+ Abnormal %']}\")\n",
    "\n",
    "classification_3_test_candidate"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "a20b736a",
   "metadata": {},
   "outputs": [],
   "source": [
    "classification_3_test_candidate.to_csv('classification_3_test_candidates.csv', index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3c88327b",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
